David J Greenblatt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9440794/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Drug Disposition in Old Age. New England Journal of Medicine, 1982, 306, 1081-1088.	13.9	605
2	Effect of Obesity on the Pharmacokinetics of Drugs in Humans. Clinical Pharmacokinetics, 2010, 49, 71-87.	1.6	594
3	Effect of Age, Gender, and Obesity on Midazolam Kinetics. Anesthesiology, 1984, 61, 27-35.	1.3	512
4	Effects of the Antifungal Agents on Oxidative Drug Metabolism. Clinical Pharmacokinetics, 2000, 38, 111-180.	1.6	471
5	Clinical Pharmacokinetics. New England Journal of Medicine, 1975, 293, 702-705.	13.9	450
6	Current Status of Benzodiazepines. New England Journal of Medicine, 1983, 309, 410-416.	13.9	367
7	Diazepam disposition determinants. Clinical Pharmacology and Therapeutics, 1980, 27, 301-312.	2.3	354
8	Clinical Pharmacokinetics of Oxazepam and Lorazepam. Clinical Pharmacokinetics, 1981, 6, 89-105.	1.6	340
9	Clinical Pharmacokinetics of Alprazolam. Clinical Pharmacokinetics, 1993, 24, 453-471.	1.6	327
10	Doseâ€Dependent Pharmacokinetics and Psychomotor Effects of Caffeine in Humans. Journal of Clinical Pharmacology, 1997, 37, 693-703.	1.0	309
11	Use of Benzodiazepines in Anxiety Disorders. New England Journal of Medicine, 1993, 328, 1398-1405.	13.9	305
12	Apparent Mechanism-based Inhibition of Human CYP2D6 in Vitro by Paroxetine: Comparison with Fluoxetine and Quinidine. Drug Metabolism and Disposition, 2003, 31, 289-293.	1.7	267
13	Sensitivity to Triazolam in the Elderly. New England Journal of Medicine, 1991, 324, 1691-1698.	13.9	262
14	Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models. Journal of Clinical Pharmacology, 2001, 41, 1149-1179.	1.0	261
15	Zolpidem for insomnia. Expert Opinion on Pharmacotherapy, 2012, 13, 879-893.	0.9	258
16	The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates. Clinical Pharmacokinetics, 2005, 44, 33-60.	1.6	250
17	EVALUATION OF 3â€2-AZIDO-3â€2-DEOXYTHYMIDINE, MORPHINE, AND CODEINE AS PROBE SUBSTRATES FOR UDP-GLUCURONOSYLTRANSFERASE 2B7 (UGT2B7) IN HUMAN LIVER MICROSOMES: SPECIFICITY AND INFLUENCE OF THE UGT2B7*2 POLYMORPHISM. Drug Metabolism and Disposition, 2003, 31, 1125-1133.	1.7	237
18	Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole. Clinical Pharmacology and Therapeutics, 1999, 66, 461-471.	2.3	234

#	Article	IF	CITATIONS
19	IN VITRO METABOLISM OF MIDAZOLAM, TRIAZOLAM, NIFEDIPINE, AND TESTOSTERONE BY HUMAN LIVER MICROSOMES AND RECOMBINANT CYTOCHROMES P450: ROLE OF CYP3A4 AND CYP3A5. Drug Metabolism and Disposition, 2003, 31, 938-944.	1.7	232
20	Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with Ritonavir. Journal of Clinical Pharmacology, 1998, 38, 106-111.	1.0	228
21	Toxicity of highâ€dose flurazepam in the elderly. Clinical Pharmacology and Therapeutics, 1977, 21, 355-361.	2.3	224
22	Kinetics of intravenous and intramuscular morphine. Clinical Pharmacology and Therapeutics, 1978, 24, 52-59.	2.3	223
23	Adverse reactions to propranolol in hospitalized medical patients: A report from the Boston Collaborative Drug Surveillance Program. American Heart Journal, 1973, 86, 478-484.	1.2	220
24	Dependence, Tolerance, and Addiction to Benzodiazepines: Clinical and Pharmacokinetic Considerations. Drug Metabolism Reviews, 1978, 8, 13-28.	1.5	217
25	Clinical Pharmacokinetics. New England Journal of Medicine, 1975, 293, 964-970.	13.9	207
26	Reduced Serum Albumin Concentration in the Elderly: A Report from the Boston Collaborative Drug Surveillance Program. Journal of the American Geriatrics Society, 1979, 27, 20-22.	1.3	190
27	In Vitro Approaches to Predicting Drug Interactions In Vivo. Biochemical Pharmacology, 1998, 55, 113-122.	2.0	188
28	Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics and Genomics, 2004, 14, 225-238.	5.7	187
29	Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2014, 13, 1083-1091.	4.9	187
30	Midazolam Hydroxylation by Human Liver Microsomes <i>In Vitro</i> : Inhibition by Fluoxetine, Norfluoxetine, and by Azole Antifungal Agents. Journal of Clinical Pharmacology, 1996, 36, 783-791.	1.0	185
31	Pharmacokinetics and Bioavailability of Intravenous, Intramuscular, and Oral Lorazepam in Humans. Journal of Pharmaceutical Sciences, 1979, 68, 57-63.	1.6	180
32	Drug Disposition in Obese Humans. Clinical Pharmacokinetics, 1986, 11, 199-213.	1.6	171
33	Molecular basis for deficient acetaminophen glucuronidation in cats. Biochemical Pharmacology, 1997, 53, 1041-1047.	2.0	170
34	Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. Clinical Pharmacology and Therapeutics, 1989, 45, 356-365.	2.3	169
35	Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clinical Pharmacology and Therapeutics, 1981, 30, 475-486.	2.3	166
36	Inhibition of Alprazolam and Desipramine Hydroxylation In Vitro by Paroxetine and Fluvoxamine. Journal of Clinical Psychopharmacology, 1995, 15, 125-131.	0.7	166

#	Article	IF	CITATIONS
37	The effect of grapefruit juice on drug disposition. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 267-286.	1.5	164
38	Saint John's wort: An in vitro analysis of P-glycoprotein induction due to extended exposure. British Journal of Pharmacology, 2001, 134, 1601-1608.	2.7	162
39	Interaction of Warfarin With Drugs, Natural Substances, and Foods. Journal of Clinical Pharmacology, 2005, 45, 127-132.	1.0	162
40	Molecular genetic basis for deficient acetaminophen glucuronidation by cats: UGT1A6 is a pseudogene, and evidence for reduced diversity of expressed hepatic UGT1A isoforms. Pharmacogenetics and Genomics, 2000, 10, 355-369.	5.7	162
41	Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clinical Pharmacology and Therapeutics, 2003, 74, 121-129.	2.3	161
42	Reduction in Lidocaine Clearance during Continuous Infusion and by Coadministration of Propranolol. New England Journal of Medicine, 1980, 303, 373-377.	13.9	160
43	Clinical Pharmacokinetics of Anxiolytics and Hypnotics in the Elderly. Clinical Pharmacokinetics, 1991, 21, 165-177.	1.6	158
44	Stereoselective Conjugation of Oxazepam by Human UDP-Glucuronosyltransferases (UGTs): S-Oxazepam Is Glucuronidated by UGT2B15, While R-Oxazepam Is Glucuronidated by UGT2B7 and UGT1A9. Drug Metabolism and Disposition, 2002, 30, 1257-1265.	1.7	155
45	Intramuscular Injection of Drugs. New England Journal of Medicine, 1976, 295, 542-546.	13.9	154
46	Drug Metabolism and Drug Interactions: Application and Clinical Value of In Vitro Models. Current Drug Metabolism, 2003, 4, 423-459.	0.7	151
47	Effect of age and gender on disposition of temazepam. Journal of Pharmaceutical Sciences, 1981, 70, 1104-1107.	1.6	150
48	Adverse Reactions to ??-Adrenergic Receptor Blocking Drugs. Drugs, 1974, 7, 118-129.	4.9	146
49	O- and N-demethylation of Venlafaxine In Vitro by Human Liver Microsomes and by Microsomes from cDNA-Transfected Cells Effect of Metabolic Inhibitors and SSRI Antidepressants. Neuropsychopharmacology, 1999, 20, 480-490.	2.8	145
50	Lorazepam kinetics in the elderly. Clinical Pharmacology and Therapeutics, 1979, 26, 103-113.	2.3	143
51	Some Biochemical Correlates of Panic Attacks with Agoraphobia and Their Response to a New Treatment. Journal of Clinical Psychopharmacology, 1984, 4, 66-75.	0.7	142
52	Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clinical Pharmacology and Therapeutics, 1992, 52, 479-486.	2.3	142
53	Five Distinct Human Cytochromes Mediate Amitriptyline Nâ€Demethylation <i>In Vitro</i> : Dominance of CYP 2C19 and 3A4. Journal of Clinical Pharmacology, 1998, 38, 112-121.	1.0	138
54	ATAZANAVIR: EFFECTS ON P-GLYCOPROTEIN TRANSPORT AND CYP3A METABOLISM IN VITRO. Drug Metabolism and Disposition, 2005, 33, 764-770.	1.7	137

#	Article	IF	CITATIONS
55	Zolpidem metabolism in vitro : responsible cytochromes, chemical inhibitors, and in vivo correlations. British Journal of Clinical Pharmacology, 1999, 48, 89-97.	1.1	136
56	Inhibition of human cytochromes P450 by components of Ginkgo bilobaâ€. Journal of Pharmacy and Pharmacology, 2010, 56, 1039-1044.	1.2	132
57	Variability of 24â€Hour Urinary Creatinine Excretion by Normal Subjects. Journal of Clinical Pharmacology, 1976, 16, 321-328.	1.0	128
58	Acute overdosage with benzodiazepine derivatives. Clinical Pharmacology and Therapeutics, 1977, 21, 497-514.	2.3	127
59	Daytime Carryover of Triazolam and Flurazepam in Elderly Insomniacs. Sleep, 1982, 5, 361-371.	0.6	127
60	Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. Journal of Pharmacokinetics and Pharmacodynamics, 1975, 3, 181-192.	0.6	122
61	Trazodone kinetics: Effect of age, gender, and obesity. Clinical Pharmacology and Therapeutics, 1987, 42, 193-200.	2.3	121
62	Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences*. Clinical Pharmacology and Therapeutics, 1998, 64, 237-247.	2.3	120
63	Pharmacokinetics of Drugs in Obesity. Clinical Pharmacokinetics, 1982, 7, 108-124.	1.6	118
64	Pharmacokinetic Comparison of Sublingual Lorazepam with Intravenous, Intramuscular, and Oral Lorazepam. Journal of Pharmaceutical Sciences, 1982, 71, 248-252.	1.6	117
65	Clinical Pharmacokinetics of the Newer Benzodiazepines. Clinical Pharmacokinetics, 1983, 8, 233-252.	1.6	117
66	Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. Journal of Pharmaceutical Sciences, 2001, 90, 1829-1837.	1.6	117
67	Clinical Pharmacokinetics of Anxiolytics and Hypnotics in the Elderly. Clinical Pharmacokinetics, 1991, 21, 262-273.	1.6	116
68	Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clinical Pharmacology and Therapeutics, 2005, 77, 373-387.	2.3	116
69	Importance of Protein Binding for the Interpretation of Serum or Plasma Drug Concentrations. Journal of Clinical Pharmacology, 1982, 22, 259-263.	1.0	115
70	Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharmaceutical Research, 2002, 19, 1038-1045.	1.7	115
71	Alprazolam-ritonavir interaction: Implications for product labeling. Clinical Pharmacology and Therapeutics, 2000, 67, 335-341.	2.3	114
72	Evaluation of Digoxin Bioavailability in Single-Dose Studies. New England Journal of Medicine, 1973, 289, 651-654.	13.9	113

#	Article	IF	CITATIONS
73	Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo*. Clinical Pharmacology and Therapeutics, 1998, 64, 553-561.	2.3	113
74	Clinical Pharmacokinetics of Quinidine. Clinical Pharmacokinetics, 1980, 5, 150-168.	1.6	111
75	Obesity, sex, and acetaminophen disposition. Clinical Pharmacology and Therapeutics, 1982, 31, 783-790.	2.3	111
76	Rapid increase in brain benzodiazepine receptor binding following defeat stress in mice. Brain Research, 1987, 414, 395-400.	1.1	111
77	Concentration-independent plasma protein binding of benzodiazepines. Journal of Pharmacy and Pharmacology, 2011, 35, 179-180.	1.2	109
78	Diazepam Kinetics in Relation to Age and Sex. Pharmacology, 1981, 23, 24-30.	0.9	108
79	Benzodiazepine Kinetics: Implications for Therapeutics and Pharmacogeriatrics. Drug Metabolism Reviews, 1983, 14, 251-292.	1.5	107
80	Metabolism of Drugs by Cytochrome P450 3A Isoforms. Clinical Pharmacokinetics, 1995, 29, 33-44.	1.6	107
81	Clinical use and toxicity of intravenous lidocaine. American Heart Journal, 1976, 92, 168-173.	1.2	105
82	Alprazolam Kinetics in the Elderly. Archives of General Psychiatry, 1983, 40, 287.	13.8	105
83	Biotransformation of Chlorzoxazone by Heptatic Microsomes from Humans and Ten Other Mammalian Species. , 1997, 18, 213-226.		105
84	UDP-Glucuronosyltransferase (UGT) 2B15 Pharmacogenetics: UGT2B15 D85Y Genotype and Gender Are Major Determinants of Oxazepam Glucuronidation by Human Liver. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 656-665.	1.3	105
85	Desipramine Pharmacokinetics When Coadministered With Paroxetine or Sertraline in Extensive Metabolizers. Journal of Clinical Psychopharmacology, 1997, 17, 284-291.	0.7	105
86	Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. European Journal of Clinical Pharmacology, 2001, 57, 31-36.	0.8	104
87	Inhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors. Journal of Clinical Pharmacology, 2001, 41, 85-91.	1.0	104
88	Validation of Serotonin (5-Hydroxtryptamine) as an in Vitro Substrate Probe for Human UDP-Glucuronosyltransferase (UGT) 1A6. Drug Metabolism and Disposition, 2003, 31, 133-139.	1.7	104
89	UDP Glucuronosyltransferase (UGT) 1A6 Pharmacogenetics: II. Functional Impact of the Three Most Common Nonsynonymous UGT1A6 Polymorphisms (S7A, T181A, and R184S). Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 1340-1346.	1.3	104
90	Absorption and Disposition of Chlordiazepoxide in Young and Elderly Male Volunteers. Journal of Clinical Pharmacology, 1977, 17, 709-718.	1.0	103

#	Article	IF	CITATIONS
91	Impairment of Diazepam Metabolism by Low-Dose Estrogen-Containing Oral-Contraceptive Steroids. New England Journal of Medicine, 1982, 306, 791-792.	13.9	103
92	Phenacetin O -deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology, 1996, 128, 398-407.	1.5	102
93	Clinical Importance of the Interaction of Diazepam and Cimetidine. New England Journal of Medicine, 1984, 310, 1639-1643.	13.9	100
94	In Vitro Prediction of the Terfenadineâ€Ketoconazole Pharmacokinetic Interaction. Journal of Clinical Pharmacology, 1994, 34, 1222-1227.	1.0	99
95	Entry of diazepam and its major metabolite into cerebrospinal fluid. Psychopharmacology, 1980, 70, 89-93.	1.5	97
96	In Vitro, Pharmacokinetic, and Pharmacodynamic Interactions of Ketoconazole and Midazolam in the Rat. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 1228-1237.	1.3	96
97	Clinical Importance of the Interaction of Phenytoin and Isoniazid. Chest, 1979, 75, 356-358.	0.4	95
98	Clinically Important Drug Interactions with Zopiclone, Zolpidem and Zaleplon. CNS Drugs, 2003, 17, 513-532.	2.7	95
99	Analysis of lorazepam and its glucoronide metabolite by electron-capture gas—liquid chromatography. Biomedical Applications, 1978, 146, 311-320.	1.7	94
100	Implications of Altered Drug Disposition in the Elderly: Studies of Benzodiazepines. Journal of Clinical Pharmacology, 1989, 29, 866-872.	1.0	94
101	Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis. PLoS ONE, 2013, 8, e61177.	1.1	93
102	Effect of Gradual Withdrawal on the Rebound Sleep Disorder after Discontinuation of Triazolam. New England Journal of Medicine, 1987, 317, 722-728.	13.9	92
103	Absolute Bioavailability of Oral and Intramuscular Diazepam. Anesthesia and Analgesia, 1983, 62, 1???8.	1.1	91
104	Pharmacokinetic studies on Ro 15-1788, a benzodiazepine receptor ligand, in the brain of the rat. Brain Research, 1984, 290, 183-186.	1.1	91
105	Alprazolam Metabolism in vitro: Studies of Human, Monkey, Mouse, and Rat Liver Microsomes. Pharmacology, 1993, 47, 268-276.	0.9	91
106	Acetaminophen kinetics in the elderly. Clinical Pharmacology and Therapeutics, 1982, 31, 151-156.	2.3	90
107	Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. British Journal of Clinical Pharmacology, 1997, 44, 495-498.	1.1	90
108	Inhibition of triazolam clearance by macrolide antimicrobial agents: In vitro correlates and dynamic consequences*. Clinical Pharmacology and Therapeutics, 1998, 64, 278-285.	2.3	90

#	Article	IF	CITATIONS
109	Microsomal Protein Concentration Modifies the Apparent Inhibitory Potency of CYP3A Inhibitors. Drug Metabolism and Disposition, 2002, 30, 1441-1445.	1.7	89
110	Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. British Journal of Clinical Pharmacology, 2003, 56, 297-304.	1.1	89
111	Mechanism of cytochrome P450-3A inhibition by ketoconazole. Journal of Pharmacy and Pharmacology, 2011, 63, 214-221.	1.2	89
112	Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors. Journal of Clinical Oncology, 2011, 29, 2933-2940.	0.8	89
113	Pharmacokinetics and pharmacodynamics of oral diazepam: Effect of dose, plasma concentration, and time. Clinical Pharmacology and Therapeutics, 1992, 52, 139-150.	2.3	88
114	Reduced quinidine clearance in elderly persons. American Journal of Cardiology, 1978, 42, 481-485.	0.7	87
115	Plasma protein binding of drugs after severe burn injury. Clinical Pharmacology and Therapeutics, 1984, 35, 535-539.	2.3	87
116	Desmethyldiazepam kinetics in the elderly after oral prazepam. Clinical Pharmacology and Therapeutics, 1980, 28, 196-202.	2.3	86
117	Digoxin disposition in obesity: Clinical pharmacokinetic investigation. American Heart Journal, 1981, 102, 740-744.	1.2	86
118	Pharmacokinetics of Diphenhydramine and a Demethylated Metabolite Following Intravenous And Oral Administration. Journal of Clinical Pharmacology, 1986, 26, 529-533.	1.0	86
119	Gender Has a Small but Statistically Significant Effect on Clearance of CYP3A Substrate Drugs. Journal of Clinical Pharmacology, 2008, 48, 1350-1355.	1.0	86
120	Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration. Journal of Clinical Pharmacology, 2014, 54, 282-290.	1.0	86
121	Anticholinergics. New England Journal of Medicine, 1973, 288, 1215-1219.	13.9	85
122	Diazepam interaction with antituberculosis drugs. Clinical Pharmacology and Therapeutics, 1981, 29, 671-678.	2.3	85
123	Impairment of Lidocaine Clearance in Elderly Male Subjects. Journal of Cardiovascular Pharmacology, 1983, 5, 1093-1096.	0.8	85
124	Pharmacokinetic Determinants of Dynamic Differences Among Three Benzodiazepine Hypnotics. Archives of General Psychiatry, 1989, 46, 326.	13.8	85
125	Multiple Human Cytochromes Contribute to Biotransformation of Dextromethorphan In-vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. Journal of Pharmacy and Pharmacology, 2011, 50, 997-1004.	1.2	85
126	Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. Journal of Pharmacology and Experimental Therapeutics, 2000, 293, 435-43.	1.3	85

#	Article	IF	CITATIONS
127	The Influence of Obesity on the Pharmacokinetics of Oral Alprazolam and Triazolam. Clinical Pharmacokinetics, 1984, 9, 177-183.	1.6	84
128	Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450â€3A in drug–drug interaction studies. British Journal of Clinical Pharmacology, 2015, 80, 342-350.	1.1	83
129	Clinical pharmacokinetics of lorazepam. Clinical Pharmacology and Therapeutics, 1976, 20, 329-341.	2.3	82
130	Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clinical Pharmacology and Therapeutics, 2004, 76, 467-479.	2.3	82
131	Human Cytochromes and Some Newer Antidepressants: Kinetics, Metabolism, and Drug Interactions. Journal of Clinical Psychopharmacology, 1999, 19, 23S-35S.	0.7	82
132	Pharmacokinetic-Pharmacodynamic Relationships For Benzodiazepines. Clinical Pharmacokinetics, 1996, 30, 52-76.	1.6	81
133	Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole*. Clinical Pharmacology and Therapeutics, 1998, 64, 661-671.	2.3	80
134	Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biological Psychiatry, 1999, 46, 839-849.	0.7	80
135	Nortriptyline E-10-Hydroxylation in Vitro Is Mediated by Human CYP2D6 (High Affinity) and CYP3A4 (Low) Tj ETQq Pharmacology, 1999, 39, 567-577.	1 1 0.784 1.0	314 rgBT /C 80
136	Fexofenadine Transport in Caco-2 Cells: Inhibition with Verapamil and Ritonavir. Journal of Clinical Pharmacology, 2002, 42, 1269-1274.	1.0	80
137	Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: In vitro and clinical studies. Clinical Pharmacology and Therapeutics, 2006, 79, 125-133.	2.3	80
138	Inhibition of Terfenadine Metabolism In Vitro by Azole Antifungal Agents and by Selective Serotonin Reuptake Inhibitor Antidepressants. Journal of Clinical Psychopharmacology, 1996, 16, 104-112.	0.7	78
139	Human cytochromes mediating N -demethylation of fluoxetine in vitro. Psychopharmacology, 1997, 132, 402-407.	1.5	77
140	Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharmaceutical Research, 2003, 20, 1177-1183.	1.7	77
141	Lorazepam. Drugs, 1981, 21, 161-200.	4.9	76
142	Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. Aids, 2000, 14, 1287.	1.0	76
143	Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology, 1983, 80, 275-278.	1.5	75
144	Prolonged Accumulation of Diazepam in Obesity. Journal of Clinical Pharmacology, 1983, 23, 369-376.	1.0	75

#	Article	IF	CITATIONS
145	Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology, 1999, 145, 113-122.	1.5	75
146	Imipramine and Buspirone in Treatment of Patients With Generalized Anxiety Disorder Who Are Discontinuing Long-Term Benzodiazepine Therapy. American Journal of Psychiatry, 2000, 157, 1973-1979.	4.0	75
147	The UDP-Glucuronosyltransferase (UGT) 1A Polymorphism c.2042C>G (rs8330) Is Associated with Increased Human Liver Acetaminophen Glucuronidation, Increased UGT1A Exon 5a/5b Splice Variant mRNA Ratio, and Decreased Risk of Unintentional Acetaminophen-Induced Acute Liver Failure. Journal of Pharmacology and Experimental Therapeutics. 2013, 345, 297-307.	1.3	75
148	Diazepam absorption: Effect of antacids and food. Clinical Pharmacology and Therapeutics, 1978, 24, 600-609.	2.3	74
149	Lidocaine disposition in obesity. American Journal of Cardiology, 1984, 53, 1183-1186.	0.7	73
150	Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo. Clinical Pharmacology and Therapeutics, 1988, 44, 326-334.	2.3	73
151	Benzodiazepine concentrations in brain directly reflect receptor occupancy: studies of diazepam, lorazepam, and oxazepam. Psychopharmacology, 1990, 102, 373-378.	1.5	73
152	Metabolism of Dextromethorphanin vitro: Involvement of Cytochromes P450 2D6 AND 3A3/4, with a Possible Role of 2E1. , 1997, 18, 227-240.		73
153	Inhibition of Desipramine Hydroxylation (Cytochrome P450-2D6) in Vitro by Quinidine and by Viral Protease Inhibitors: Relation to Drug Interactions in Vivo. Journal of Pharmaceutical Sciences, 1998, 87, 1184-1189.	1.6	73
154	Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats. Xenobiotica, 2004, 34, 133-150.	0.5	72
155	A randomized trial of mexiletine in ALS. Neurology, 2016, 86, 1474-1481.	1.5	72
156	Bioavailability of Drugs. Clinical Pharmacokinetics, 1976, 1, 36-51.	1.6	71
157	THE NOVEL UGT1A9 INTRONIC I399 POLYMORPHISM APPEARS AS A PREDICTOR OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN GLUCURONIDATION LEVELS IN THE LIVER. Drug Metabolism and Disposition, 2006, 34, 1220-1228.	1.7	71
158	Comparison of Duloxetine, Escitalopram, and Sertraline Effects on Cytochrome P450 2D6 Function in Healthy Volunteers. Journal of Clinical Psychopharmacology, 2007, 27, 28-34.	0.7	71
159	Effects of three antibiotics on theophylline kinetics. Clinical Pharmacology and Therapeutics, 1979, 26, 36-40.	2.3	70
160	UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology, 2005, 42, 448-457.	3.6	70
161	Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir. Clinical Pharmacology and Therapeutics, 2006, 79, 243-254.	2.3	70
162	Pomegranate Juice Does Not Impair Clearance of Oral or Intravenous Midazolam, a Probe for Cytochrome P450-3A Activity: Comparison With Grapefruit Juice. Journal of Clinical Pharmacology, 2007, 47, 286-294.	1.0	70

#	Article	IF	CITATIONS
163	Absolute and Relative Bioavailability of Oral Acetaminophen Preparations. Journal of Pharmaceutical Sciences, 1983, 72, 955-958.	1.6	69
164	Phenelzine and the Dream Machine—Ramblings and Reflections. Journal of Clinical Psychopharmacology, 1985, 5, 65.	0.7	69
165	Benzodiazepines. New England Journal of Medicine, 1974, 291, 1239-1243.	13.9	67
166	Spironolactone. American Heart Journal, 1978, 96, 389-400.	1.2	67
167	Absorption and disposition of ibuprofen in the elderly. Arthritis and Rheumatism, 1984, 27, 1066-1069.	6.7	67
168	Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 129-136.	0.9	67
169	Norcocaine and N-Hydroxynorcocaine Formation in Human Liver Microsomes: Role of Cytochrome P-450 3A4. Pharmacology, 1993, 46, 294-300.	0.9	65
170	Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 129-136.	0.9	65
171	Influence of fruit juices on drug disposition: discrepancies between <i>in vitro</i> and clinical studies. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 381-393.	1.5	65
172	Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. British Journal of Clinical Pharmacology, 2013, 75, 450-462.	1.1	65
173	Imipramine disposition in users of oral contraceptive steroids. Clinical Pharmacology and Therapeutics, 1984, 35, 792-797.	2.3	64
174	Human cytochromes P450 mediating phenacetin Oâ€deethylation in vitro: Validation of the high affinity component as an index of CYP1A2 activity. Journal of Pharmaceutical Sciences, 1998, 87, 1502-1507.	1.6	64
175	Evidence for oxazepam as an <i>in vivo</i> probe of UGT2B15: oxazepam clearance is reduced by <i>UGT2B15</i> D85Y polymorphism but unaffected by <i>UGT2B17</i> deletion. British Journal of Clinical Pharmacology, 2009, 68, 721-730.	1.1	64
176	Clinical Pharmacokinetics of Chlordiazepoxide. Clinical Pharmacokinetics, 1978, 3, 381-394.	1.6	63
177	Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. Clinical Pharmacology and Therapeutics, 1978, 24, 308-315.	2.3	63
178	Liver injury associated with ketoconazole: Review of the published evidence. Journal of Clinical Pharmacology, 2014, 54, 1321-1329.	1.0	63
179	Clinical Toxicity of Theophylline in Relation to Cigarette Smoking. Chest, 1978, 73, 455-459.	0.4	62
180	Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate. Psychopharmacology, 1981, 75, 193-197.	1.5	62

#	Article	IF	CITATIONS
181	Pharmacokinetic and Clinical Implications of Quinidine Protein Binding. Journal of Pharmaceutical Sciences, 1979, 68, 466-470.	1.6	61
182	Age and Gender Effects on the Pharmacokinetics and Pharmacodynamics of Ramelteon, a Hypnotic Agent Acting via Melatonin Receptors MT1and MT2. Journal of Clinical Pharmacology, 2007, 47, 485-496.	1.0	59
183	Extensive Impairment of Triazolam and Alprazolam Clearance by Short-Term Low-Dose Ritonavir. Journal of Clinical Psychopharmacology, 1999, 19, 293-296.	0.7	58
184	Clinical toxicity of furosemide in hospitalized patients. American Heart Journal, 1977, 94, 6-13.	1.2	57
185	Quantitation by Gas Chromatography of the 1- and 4-Hydroxy Metabolites of Midazolam in Human Plasma. Pharmacology, 1984, 29, 158-164.	0.9	57
186	Relative Contribution of CYP3A to Amitriptyline Clearance in Humans: In Vitro and In Vivo Studies. Journal of Clinical Pharmacology, 2001, 41, 1043-1054.	1.0	57
187	Analysis of Drug Interactions Involving Fruit Beverages and Organic Anionâ€Transporting Polypeptides. Journal of Clinical Pharmacology, 2009, 49, 1403-1407.	1.0	57
188	Age-Related Differences in CYP3A Expression and Activity in the Rat Liver, Intestine, and Kidney. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 720-729.	1.3	56
189	Flurazepam hydrochloride. Clinical Pharmacology and Therapeutics, 1975, 17, 1-14.	2.3	55
190	Pharmacokinetic Aspects of Drug Therapy in the Elderly. Therapeutic Drug Monitoring, 1986, 8, 249-255.	1.0	55
191	Chronic benzodiazepine administration. Biochemical Pharmacology, 1989, 38, 3773-3777.	2.0	55
192	Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: Kinetic-dynamic studies. Clinical Pharmacology and Therapeutics, 1994, 56, 100-111.	2.3	55
193	Effect of Food on Acetaminophen Absorption in Young and Elderly Subjects. Journal of Clinical Pharmacology, 1982, 22, 571-576.	1.0	54
194	Cortisol response to diazepam: its relationship to age, dose, duration of treatment, and presence of generalized anxiety disorder. Psychopharmacology, 2005, 178, 1-8.	1.5	54
195	Dynamics and Kinetics of a Modified-Release Formulation of Zolpidem: Comparison With Immediate-Release Standard Zolpidem and Placebo. Journal of Clinical Pharmacology, 2006, 46, 1469-1480.	1.0	54
196	Slow Absorption of Intramuscular Chlordiazepoxide. New England Journal of Medicine, 1974, 291, 1116-1118.	13.9	53
197	Sedative effects and impaired learning and recall after single oral doses of lorazepam. Clinical Pharmacology and Therapeutics, 1986, 39, 526-530.	2.3	53
198	In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. Biological Psychiatry, 2000, 47, 655-661.	0.7	53

#	Article	IF	CITATIONS
199	Short-Term Exposure to Low-Dose Ritonavir Impairs Clearance and Enhances Adverse Effects of Trazodone. Journal of Clinical Pharmacology, 2003, 43, 414-422.	1.0	53
200	Role of CYP3A and CYP2E1 in Alcohol-Mediated Increases in Acetaminophen Hepatotoxicity: Comparison of Wild-Type and Cyp2e1(–/–) Mice. Drug Metabolism and Disposition, 2007, 35, 1223-1231.	1.7	53
201	Candidate Gene Polymorphisms in Patients with Acetaminophen-Induced Acute Liver Failure. Drug Metabolism and Disposition, 2014, 42, 28-32.	1.7	53
202	Chlordiazepoxide and oxazepam disposition in cirrhosis. Clinical Pharmacology and Therapeutics, 1979, 26, 240-246.	2.3	52
203	Impairment of antipyrine metabolism by low-dose oral contraceptive steroids. Clinical Pharmacology and Therapeutics, 1981, 29, 106-110.	2.3	52
204	Benzodiazepine Sensitivity in Panic Disorder: Effects of Chronic Alprazolam Treatment. Neuropsychopharmacology, 1995, 12, 147-157.	2.8	52
205	UDP Glucuronosyltransferase (UGT) 1A6 Pharmacogenetics: I. Identification of Polymorphisms in the 5′-Regulatory and Exon 1 Regions, and Association with Human Liver UGT1A6 Gene Expression and Glucuronidation. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 1331-1339.	1.3	52
206	Ginkgo bilobaDoes Not Alter Clearance of Flurbiprofen, a Cytochrome P450-2C9 Substrate. Journal of Clinical Pharmacology, 2006, 46, 214-221.	1.0	52
207	Prolongation of Drug Half-Life due to Obesity: Studies of Desmethyldiazepam (Clorazepate). Journal of Pharmaceutical Sciences, 1982, 71, 942-944.	1.6	51
208	Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. Clinical Pharmacology and Therapeutics, 1983, 33, 628-632.	2.3	51
209	Inhibition of Human Cytochrome P450â€3A Isoforms by Fluoxetine and Norfluoxetine: <i>In Vitro</i> and <i>In Vivo</i> Studies. Journal of Clinical Pharmacology, 1996, 36, 792-798.	1.0	51
210	Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. British Journal of Clinical Pharmacology, 2005, 60, 486-493.	1.1	51
211	Pharmacokinetics and Pharmacodynamics of Multiple Sublingual Buprenorphine Tablets in Dose-Escalation Trials. Journal of Clinical Pharmacology, 2006, 46, 179-192.	1.0	51
212	Drug Interactions With Grapefruit Juice: An Update. Journal of Clinical Psychopharmacology, 2001, 21, 357-359.	0.7	51
213	Repeated diazepam dosing in cirrhotic patients: Cumulation and sedation. Clinical Pharmacology and Therapeutics, 1983, 33, 471-476.	2.3	50
214	Bromazepam pharmacokinetics: Influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clinical Pharmacology and Therapeutics, 1987, 41, 562-570.	2.3	50
215	Race, Gender, and Genetic Polymorphism Contribute to Variability in Acetaminophen Pharmacokinetics, Metabolism, and Protein-Adduct Concentrations in Healthy African-American and European-American Volunteers. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 431-440.	1.3	49
216	Influence of serum digoxin concentration measurements on frequency of digitoxicity. Clinical Pharmacology and Therapeutics, 1974, 16, 284-287.	2.3	48

#	Article	IF	CITATIONS
217	Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption. Clinical Pharmacology and Therapeutics, 1976, 19, 234-239.	2.3	48
218	Ibuprofen disposition in obese individuals. Arthritis and Rheumatism, 1985, 28, 1117-1121.	6.7	48
219	Interaction of caffeine with the GABAA receptor complex: alterations in receptor function but not ligand binding. European Journal of Pharmacology, 1989, 172, 453-459.	2.7	48
220	EVALUATION OF 5-HYDROXYTRYPTOPHOL AND OTHER ENDOGENOUS SEROTONIN (5-HYDROXYTRYPTAMINE) ANALOGS AS SUBSTRATES FOR UDP-GLUCURONOSYLTRANSFERASE 1A6. Drug Metabolism and Disposition, 2004, 32, 862-869.	1.7	48
221	FACTORS INFLUENCING MIDAZOLAM HYDROXYLATION ACTIVITY IN HUMAN LIVER MICROSOMES. Drug Metabolism and Disposition, 2006, 34, 1198-1207.	1.7	48
222	Age Does Not Alter Acetaminophen Absorption. Journal of the American Geriatrics Society, 1982, 30, 240-244.	1.3	47
223	Pharmacokinetics and Clinical Effects of Alprazolam Following Single and Multiple Oral Doses in Patients With Panic Disorder. Journal of Clinical Pharmacology, 1986, 26, 292-298.	1.0	47
224	Relative Quantities of Catalytically Active CYP 2C9 and 2C19 in Human Liver Microsomes: Application of the Relative Activity Factor Approach. Journal of Pharmaceutical Sciences, 1998, 87, 845-853.	1.6	47
225	Kinetics of Diazepam, Midazolam, and Lorazepam in Cigarette Smokers. Chest, 1985, 87, 223-226.	0.4	46
226	Population Pharmacokinetics of Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder. Journal of Clinical Pharmacology, 1999, 39, 775-785.	1.0	46
227	LEVOTHYROXINE UP-REGULATES P-GLYCOPROTEIN INDEPENDENT OF THE PREGNANE X RECEPTOR. Drug Metabolism and Disposition, 2004, 32, 779-782.	1.7	46
228	The Clinician and Drug Interactions-An Update. Journal of Clinical Psychopharmacology, 1996, 16, 197-201.	0.7	46
229	Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin. Arthritis and Rheumatism, 1986, 29, 971-980.	6.7	45
230	Enhanced Bioavailability of Triazolam Following Sublingual Versus Oral Administration. Journal of Clinical Pharmacology, 1986, 26, 208-210.	1.0	45
231	Chronic benzodiazepine administration. Psychopharmacology, 1991, 104, 225-230.	1.5	45
232	Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4â€dimethylâ€benzisoâ€(2H)â€selenazine (ALTâ€2074), an experimental catalytic mimic of glutathione oxidaso British Journal of Clinical Pharmacology, 2009, 68, 920-927.	2.1.1	45
233	Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells. Journal of Pharmacy and Pharmacology, 2010, 59, 947-953.	1.2	45
234	Clinical pharmacokinetics of lorazepam; II. Intramuscular injection. Clinical Pharmacology and Therapeutics, 1977, 21, 222-230.	2.3	44

#	Article	IF	CITATIONS
235	Prazepam and Lorazepam, Two New Benzodiazepines. New England Journal of Medicine, 1978, 299, 1342-1344.	13.9	44
236	Modulation of benzodiazepine receptor binding in mouse brain by adrenalectomy and steroid replacement. Brain Research, 1988, 446, 314-320.	1.1	44
237	A Large-Sample Study of Diazepam Pharmacokinetics. Therapeutic Drug Monitoring, 1989, 11, 652-657.	1.0	44
238	Personality and benzodiazepine sensitivity in anxious patients and control subjects. Psychiatry Research, 1993, 47, 151-162.	1.7	44
239	Inhibition of cytochrome P450 by nefazodone in vitro : studies of dextromethorphan O ―and N â€demethylation. British Journal of Clinical Pharmacology, 1996, 41, 339-343.	1.1	44
240	Pharmacokinetics and Pharmacodynamics of Diphenhydramine 25 mg in Young and Elderly Volunteers. Journal of Clinical Pharmacology, 1998, 38, 603-609.	1.0	44
241	The Absence of an Interaction Between Warfarin and Cranberry Juice: A Randomized, Doubleâ€Blind Trial. Journal of Clinical Pharmacology, 2009, 49, 824-830.	1.0	44
242	Relationship of In Vitro Data on Drug Metabolism to In Vivo Pharmacokinetics and Drug Interactions. Journal of Clinical Psychopharmacology, 1996, 16, 267-272.	0.7	44
243	Kinetics of high-dose intravenous morphine in cardiac surgery patients. Clinical Pharmacology and Therapeutics, 1976, 19, 752-756.	2.3	43
244	Clobazam Kinetics: Intrasubject Variability and Effect of Food on Absorption. Journal of Clinical Pharmacology, 1982, 22, 69-73.	1.0	43
245	Diazepam absorption. Digestive Diseases and Sciences, 1982, 27, 225-230.	1.1	42
246	Benzodiazepine pharmacodynamics: utility of eye movement measures. Psychopharmacology, 1993, 110, 85-91.	1.5	42
247	Biochemical Basis for Deficient Paracetamol Glucuronidation in Cats: an Interspecies Comparison of Enzyme Constraint in Liver Microsomes. Journal of Pharmacy and Pharmacology, 2011, 49, 446-449.	1.2	42
248	From Disordered Eating to Addiction. Journal of Clinical Psychopharmacology, 2012, 32, 376-389.	0.7	42
249	Zolpidem and Gender: Are Women Really At Risk?. Journal of Clinical Psychopharmacology, 2019, 39, 189-199.	0.7	42
250	Clinical Pharmacokinetics of Antidepressants in the Elderly. Clinical Pharmacokinetics, 1993, 24, 141-160.	1.6	41
251	Characterization of Six in vitro Reactions Mediated by Human Cytochrome P450: Application to the Testing of Cytochrome P450-Directed Antibodies. Pharmacology, 1996, 52, 125-134.	0.9	41
252	Pharmacokinetics of Efavirenz When Coâ€administered With Rifampin in TB/HIV Coâ€infected Patients: Pharmacogenetic Effect of <i>CYP2B6</i> Variation. Journal of Clinical Pharmacology, 2008, 48, 1032-1040.	1.0	41

#	Article	IF	CITATIONS
253	Benzodiazepine overdosage: Plasma concentrations and clinical outcome. Psychopharmacology, 1981, 73, 381-383.	1.5	40
254	Propranolol interactions with diazepam, lorazepam, and alprazolam. Clinical Pharmacology and Therapeutics, 1984, 36, 451-455.	2.3	40
255	Benzodiazepine receptor binding of nonbenzodiazepines in vivo: Alpidem, zolpidem and zopiclone. Brain Research Bulletin, 1992, 29, 905-908.	1.4	40
256	Eye Movement Effects of Diazepam in Sons of Alcoholic Fathers and Male Control Subjects. Alcoholism: Clinical and Experimental Research, 1994, 18, 324-332.	1.4	40
257	Balancing efficacy and safety in the use of oral sedation in dental outpatients. Journal of the American Dental Association, 2006, 137, 502-513.	0.7	40
258	Fentanyl Clearance and Volume of Distribution Are Increased in Patients With Major Burns. Journal of Clinical Pharmacology, 2007, 47, 674-680.	1.0	40
259	Inhibition of human cytochromes P450 <i>in vitro</i> by ritonavir and cobicistat. Journal of Pharmacy and Pharmacology, 2017, 69, 1786-1793.	1.2	40
260	Drugs Five Years Later. Annals of Internal Medicine, 1975, 83, 237.	2.0	39
261	Age, sex, and nitrazepam kinetics: Relation to antipyrine disposition. Clinical Pharmacology and Therapeutics, 1985, 38, 697-703.	2.3	39
262	Desmethyldiazepam Pharmacokinetics: Studies Following Intravenous and Oral Desmethyldiazepam, Oral Clorazepate, and Intravenous Diazepam. Journal of Clinical Pharmacology, 1988, 28, 853-859.	1.0	39
263	Appropriate Use and Regulatory Control of Benzodiazepines. Journal of Clinical Pharmacology, 1991, 31, 781-784.	1.0	39
264	Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level. Journal of Pharmacological and Toxicological Methods, 2000, 43, 41-54.	0.3	39
265	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through <i>in-vitro</i> inhibition studies. Journal of Pharmacy and Pharmacology, 2017, 69, 1762-1772.	1.2	39
266	Gabapentin and Pregabalin for the Treatment of Anxiety Disorders. Clinical Pharmacology in Drug Development, 2018, 7, 228-232.	0.8	39
267	Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection. Journal of Clinical Pharmacology, 2018, 58, 533-540.	1.0	39
268	Alprazolam Is Another Substrate for Human Cytochrome P450-3A Isoforms. Journal of Clinical Psychopharmacology, 1998, 18, 256.	0.7	39
269	Trimipramine kinetics and absolute bioavailability: Use of gas-liquid chromatography with nitrogen-phosphorus detection. Clinical Pharmacology and Therapeutics, 1984, 35, 348-353.	2.3	38
270	Simple and rapid liquid chromatography method for determination of efavirenz in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 835, 131-135.	1.2	38

#	Article	IF	CITATIONS
271	Role of NADPH-Cytochrome P450 Reductase and Cytochrome- <i>b</i> ₅ /NADH- <i>b</i> ₅ Reductase in Variability of CYP3A Activity in Human Liver Microsomes. Drug Metabolism and Disposition, 2009, 37, 90-96.	1.7	38
272	Altered Drug Disposition Following Bariatric Surgery: A Research Challenge. Clinical Pharmacokinetics, 2015, 54, 573-579.	1.6	38
273	Meprobamate: A Study of Irrational Drug Use. American Journal of Psychiatry, 1971, 127, 1297-1303.	4.0	37
274	Bioavailability of digoxin tablets and elixir in the fasting and postprandial states. Clinical Pharmacology and Therapeutics, 1974, 16, 444-448.	2.3	37
275	Kinetics of intravenous chlordiazepoxide: Sex differences in drug distribution. Clinical Pharmacology and Therapeutics, 1977, 22, 893-903.	2.3	37
276	Single and multiple dose pharmacokinetics of oral quinidine sulfate and gluconate. American Journal of Cardiology, 1978, 41, 770-777.	0.7	37
277	Kinetics and dynamics of lorazepam during and after continuous intravenous infusion. Critical Care Medicine, 2000, 28, 2750-2757.	0.4	37
278	Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques. Journal of Clinical Pharmacology, 2002, 42, 376-382.	1.0	37
279	Comparison of Pharmacokinetic Profiles of Zolpidem Buffered Sublingual Tablet and Zolpidem Oral Immediate-Release Tablet: Results from a Single-Center, Single-Dose, Randomized, Open-Label Crossover Study in Healthy Adults. Clinical Therapeutics, 2013, 35, 604-611.	1.1	37
280	The Clinical Choice of Sedative-Hypnotics. Annals of Internal Medicine, 1972, 77, 91.	2.0	36
281	Dose-independent pharmacokinetics of digoxin in humans. American Heart Journal, 1978, 96, 507-511.	1.2	36
282	Single- and multiple-dose kinetics of estazolam, a triazolo benzodiazepine. Psychopharmacology, 1979, 66, 267-274.	1.5	36
283	Ranitidine does not impair oxidative or conjugative metabolism: Noninteraction with antipyrine, diazepam, and lorazepam. Clinical Pharmacology and Therapeutics, 1984, 35, 188-192.	2.3	36
284	P-glycoprotein Interactions of Nefazodone and Trazodone in Cell Culture. Journal of Clinical Pharmacology, 2001, 41, 708-714.	1.0	36
285	Effect of a cocktail on diazepam absorption. Psychopharmacology, 1978, 57, 199-203.	1.5	35
286	Plasma Alprazolam Concentrations. Archives of General Psychiatry, 1993, 50, 715.	13.8	35
287	Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N -demethylation. British Journal of Clinical Pharmacology, 1996, 41, 593-604.	1.1	35
288	Pharmacokinetics and Clinical Effects of Amantadine in Drugâ€Induced Extrapyramidal Symptoms. Journal of Clinical Pharmacology, 1977, 17, 704-708.	1.0	34

#	Article	IF	CITATIONS
289	Single- and multiple-dose kinetics of oral lorazepam in humans: The predictability of accumulation. Journal of Pharmacokinetics and Pharmacodynamics, 1979, 7, 159-179.	0.6	34
290	Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. Clinical Pharmacology and Therapeutics, 1985, 38, 648-651.	2.3	34
291	Biotransformation of Mestranol to Ethinyl Estradiol In Vitro: The Role of Cytochrome Pâ€450 2C9 and Metabolic Inhibitors. Journal of Clinical Pharmacology, 1997, 37, 193-200.	1.0	34
292	EXTRAPOLATING IN VITRO DATA ON DRUG METABOLISM TO IN VIVO PHARMACOKINETICS: EVALUATION OF THE PHARMACOKINETIC INTERACTION BETWEEN AMITRIPTYLINE AND FLUOXETINE. Drug Metabolism Reviews, 1999, 31, 545-560.	1.5	34
293	INTERACTION OF TRIAZOLAM AND KETOCONAZOLE IN P-GLYCOPROTEIN-DEFICIENT MICE. Drug Metabolism and Disposition, 2004, 32, 800-804.	1.7	34
294	The Effect of Age on P-Glycoprotein Expression and Function in the Fischer-344 Rat. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 730-736.	1.3	34
295	Role of the nuclear receptor PXR in acetaminophen hepatotoxicity. Drug Metabolism and Disposition, 2005, 33, 1827-36.	1.7	34
296	Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. British Journal of Clinical Pharmacology, 2011, 72, 434-441.	1.1	34
297	The Archaic Barbiturate Hypnotics. New England Journal of Medicine, 1974, 291, 790-791.	13.9	33
298	Cimetidine Impairs Clearance of Antipyrine and Desmethyldiazepam in the Elderly. Journal of the American Geriatrics Society, 1982, 30, 684-689.	1.3	33
299	Reduced Single-dose Clearance of Clobazam in Elderly Men Predicts Increased Multiple-dose Accumulation1. Clinical Pharmacokinetics, 1983, 8, 83-94.	1.6	33
300	Pharmacokinetics, Central Nervous System Uptake, and Lipid Solubility of Propranolol, Acebutolol, and Sotalol. Cardiology, 1984, 71, 307-314.	0.6	33
301	Benzodiazepine Receptor Binding of Triazolobenzodiazepines In Vivo: Increased Receptor Number with Low-Dose Alprazolam. Journal of Neurochemistry, 1987, 49, 1595-1601.	2.1	33
302	Kinetics, brain uptake, and receptor binding characteristics of flurazepam and its metabolites. Psychopharmacology, 1988, 94, 386-91.	1.5	33
303	Age and Gender Effects on Chlordiazepoxide Kinetics: Relation to Antipyrine Disposition. Pharmacology, 1989, 38, 327-334.	0.9	33
304	Response to Diazepam in Sons of Alcoholics. Alcoholism: Clinical and Experimental Research, 1992, 16, 1057-1063.	1.4	33
305	Cognitive effects of β-adrenergic antagonists after single doses: Pharmacokinetics and pharmacodynamics of propranolol, atenolol, lorazepam, and placebo. Clinical Pharmacology and Therapeutics, 1993, 53, 577-584.	2.3	33
306	Ritonavir Greatly Impairs CYP3A Activity in HIV Infection With Chronic Viral Hepatitis. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 358-368.	0.9	33

#	Article	IF	CITATIONS
307	Effect of lipophilicity on drug distribution and elimination: Influence of obesity. British Journal of Clinical Pharmacology, 2021, 87, 3197-3205.	1.1	33
308	A Clinical Study or Flurazepam. Sleep, 1982, 5, 350-360.	0.6	32
309	Cimetidine impairs nitrazepam clearance. Clinical Pharmacology and Therapeutics, 1983, 34, 227-230.	2.3	32
310	Triazolam and ethanol interaction: Kinetic and dynamic consequences. Clinical Pharmacology and Therapeutics, 1985, 37, 558-562.	2.3	32
311	Oxidative versus conjugative biotransformation of temazepam. Biopharmaceutics and Drug Disposition, 1990, 11, 499-506.	1.1	32
312	In Vitro Interactions of Water-Soluble Garlic Components with Human Cytochromes P450. Journal of Nutrition, 2006, 136, 806S-809S.	1.3	32
313	Ritonavir Has Minimal Impact on the Pharmacokinetic Disposition of a Single Dose of Bupropion Administered to Human Volunteers. Journal of Clinical Pharmacology, 2006, 46, 567-576.	1.0	32
314	Psychotropic Drug Prescribing in the United States. Journal of Clinical Psychopharmacology, 2011, 31, 1-3.	0.7	32
315	Update on Psychotropic Drug Prescribing in the United States. Journal of Clinical Psychopharmacology, 2018, 38, 1-4.	0.7	32
316	Intravenous digoxin as a bioavailability standard: Slow infusion and rapid injection. Clinical Pharmacology and Therapeutics, 1974, 15, 510-513.	2.3	31
317	Clinical Pharmacokinetics of Lorazepam. III. Intravenous Injection. Preliminary Results. Journal of Clinical Pharmacology, 1977, 17, 490-494.	1.0	31
318	Antipyrine Absorption and Disposition in the Elderly. Pharmacology, 1988, 36, 125-133.	0.9	31
319	The NMDA Receptor Competitive Antagonist CPP Modulates Benzodiazepine Tolerance and Discontinuation. Pharmacology, 1997, 55, 217-227.	0.9	31
320	Kinetic equivalence of stable-isotope-labeled and unlabeled phenytoin. Clinical Pharmacology and Therapeutics, 1981, 29, 511-515.	2.3	30
321	A simplex procedure for fitting nonlinear pharmacokinetic models. Computers in Biology and Medicine, 1987, 17, 199-208.	3.9	30
322	Metronidazole Impairs Clearance of Phenytoin but Not of Alprazolam or Lorazepam. Journal of Clinical Pharmacology, 1988, 28, 240-245.	1.0	30
323	Chronic morphine administration augments benzodiazepine binding and GABAA receptor function. Psychopharmacology, 1990, 101, 545-549.	1.5	30
324	Sources of variability in ketoconazole inhibition of human cytochrome P450 3A <i>in vitro</i> . Xenobiotica, 2010, 40, 713-720.	0.5	30

#	Article	IF	CITATIONS
325	A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 508-513.	2.3	30
326	Entry of quinidine into cerebrospinal fluid. American Heart Journal, 1980, 100, 341-346.	1.2	29
327	Impairment of Digoxin Clearance by Coadministration of Quinidine. Journal of Clinical Pharmacology, 1981, 21, 396-400.	1.0	29
328	Studies With Stable Isotopes II: Phenobarbital Pharmacokinetics During Monotherapy. Journal of Clinical Pharmacology, 1985, 25, 51-58.	1.0	29
329	Interaction of Diazepam With Famotidine and Cimetidine, Two H ₂ â€Receptor Antagonists. Journal of Clinical Pharmacology, 1986, 26, 299-303.	1.0	29
330	Lorazepam conjugation is unimpaired in burn trauma. Clinical Pharmacology and Therapeutics, 1988, 43, 250-255.	2.3	29
331	Clearance of the Antihistamine Doxylamine. Clinical Pharmacokinetics, 1989, 16, 312-316.	1.6	29
332	Effect of zolpidem on human Cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharmaceutics and Drug Disposition, 2002, 23, 361-367.	1.1	29
333	Pharmocokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test. British Journal of Clinical Pharmacology, 2005, 60, 244-248.	1.1	29
334	Human Cytochromes Mediating Sertraline Biotransformation: Seeking Attribution. Journal of Clinical Psychopharmacology, 1999, 19, 489-493.	0.7	29
335	Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. Aids, 2003, 17, 1092-4.	1.0	29
336	Meprobamate Overdosage: A Continuing Problem. Clinical Toxicology, 1977, 11, 501-515.	0.5	28
337	Pharmacokinetics and bioavailability of digoxin capsules, solution and tablets after single and multiple doses. American Journal of Cardiology, 1978, 42, 129-136.	0.7	28
338	Effect of age and Billroth gastrectomy on absorption of desmethyldiazepam from clorazepate. Clinical Pharmacology and Therapeutics, 1979, 26, 449-456.	2.3	28
339	Noninteraction of Digitoxin and Quinidine. New England Journal of Medicine, 1980, 303, 672-674.	13.9	28
340	Physiologic Changes in Old Age: Relation to Altered Drug Disposition. Journal of the American Geriatrics Society, 1982, 30, S6-10.	1.3	28
341	Caffeineâ€induced behavioural stimulation is dose―and concentrationâ€dependent. British Journal of Pharmacology, 1990, 100, 435-440.	2.7	28
342	Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A. Biopharmaceutics and Drug Disposition, 2004, 25, 283-289.	1.1	28

#	Article	IF	CITATIONS
343	Kinetics and Dynamics of Intravenous Adinazolam, N-Desmethyl Adinazolam, and Alprazolam in Healthy Volunteers. Journal of Clinical Pharmacology, 2005, 45, 529-537.	1.0	28
344	Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. Journal of Pharmacy and Pharmacology, 2010, 55, 381-386.	1.2	28
345	Designer Benzodiazepines: A Review of Published Data and Public Health Significance. Clinical Pharmacology in Drug Development, 2019, 8, 266-269.	0.8	28
346	Singleâ€Dose Pharmacokinetics and Pharmacodynamics of Alprazolam in Elderly and Young Subjects. Journal of Clinical Pharmacology, 1998, 38, 14-21.	1.0	27
347	Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(â^'/â^') mouse liver microsomes. Biochemical Pharmacology, 1999, 57, 1227-1232.	2.0	27
348	Inhibition of human cytochrome P450 isoformsin vitro by zafirlukast. Biopharmaceutics and Drug Disposition, 1999, 20, 385-388.	1.1	27
349	Effect of Age on in Vitro Triazolam Biotransformation in Male Human Liver Microsomes. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 874-879.	1.3	27
350	Effect of Propranolol on Pharmacokinetics and Acute Electrocardiographic Changes following Intravenous Quinidine in Humans. Pharmacology, 1978, 17, 301-306.	0.9	26
351	Methods for the determination of lorazepam and chlordiazepoxide and metabolites in brain tissue. Biomedical Applications, 1983, 277, 201-208.	1.7	26
352	Alprazolam Pharmacokinetics in Women on Lowâ€Đose Oral Contraceptives. Journal of Clinical Pharmacology, 1988, 28, 454-457.	1.0	26
353	Inhibition of acetaminophen and lorazepam glucuronidationin vitro by probenecid. Biopharmaceutics and Drug Disposition, 1993, 14, 119-130.	1.1	26
354	In Vitro Biotransformation of Sildenafil (Viagra) in the Male Rat: The Role of CYP2C11. Drug Metabolism and Disposition, 2002, 30, 655-657.	1.7	26
355	Cerebrospinal fluid uptake and peripheral distribution of centrally acting drugs: Relation to lipid solubility. Journal of Pharmacy and Pharmacology, 2011, 37, 428-431.	1.2	26
356	Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen. British Journal of Clinical Pharmacology, 2015, 80, 1076-1085.	1.1	26
357	Evidenceâ€based choice of ritonavir as index CYP3A inhibitor in drugâ€drug interaction studies. Journal of Clinical Pharmacology, 2016, 56, 152-156.	1.0	26
358	International Task Force on Benzodiazepines. Psychotherapy and Psychosomatics, 2018, 87, 193-194.	4.0	26
359	The behavioural effects of Lorazepam are poorly related to its concentration in the brain. Life Sciences, 1983, 32, 2033-2040.	2.0	25
360	Absolute bioavailability of imipramine: Influence of food. Psychopharmacology, 1984, 83, 104-106.	1.5	25

#	Article	IF	CITATIONS
361	The Neuropsychiatric Effects of Aspartame in Normal Volunteers. Journal of Clinical Pharmacology, 1990, 30, 454-460.	1.0	25
362	Alterations in Pharmacodynamics of Anxiolytics in Abstinent Alcoholic Men: Subjective Responses, Abuse Liability, and Electroencephalographic Effects of Alprazolam, Diazepam, and Buspirone. Journal of Clinical Pharmacology, 1997, 37, 64-73.	1.0	25
363	Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms. Biological Psychiatry, 1997, 41, 377-380.	0.7	25
364	Comparative Abuse Liability and Pharmacological Effects of Meprobamate, Triazolam, and Butabarbital. Journal of Clinical Psychopharmacology, 2003, 23, 269-280.	0.7	25
365	Kinetics and EEG Effects of Midazolam during and after 1-Minute, 1-Hour, and 3-Hour Intravenous Infusions. Journal of Clinical Pharmacology, 2004, 44, 605-611.	1.0	25
366	Pomegranate Juice and Pomegranate Extract Do Not Impair Oral Clearance of Flurbiprofen in Human Volunteers: Divergence From In Vitro Results. Clinical Pharmacology and Therapeutics, 2012, 92, 651-657.	2.3	25
367	Tricyclic Antidepressant Determination in Human Plasma by Gas-Liquid Chromatography Using Nitrogen-Phosphorous Detection: Application to Single-Dose Pharmacokinetic Studies. Pharmacology, 1981, 23, 57-63.	0.9	24
368	Pharmacokinetic Equivalence of Stable—Isotope‣abeled and Unlabeled Drugs. Phenobarbital in Man. Journal of Clinical Pharmacology, 1982, 22, 309-315.	1.0	24
369	Is Volume of Distribution at Steady State a Meaningful Kinetic Variable?. Journal of Clinical Pharmacology, 1983, 23, 391-400.	1.0	24
370	Glycoconjugates as noninvasive probes of intrahepatic metabolism: I. Kinetics of label incorporation with evidence of a common precursor UDP-glucose pool for secreted glycoconjugates. Metabolism: Clinical and Experimental, 1987, 36, 988-994.	1.5	24
371	Benzodiazepine receptor binding: Influence of physiologic and pharmacologic factors. Biopharmaceutics and Drug Disposition, 1987, 8, 103-114.	1.1	24
372	Low-dose alprazolam augments motor activity in mice. Pharmacology Biochemistry and Behavior, 1988, 30, 511-513.	1.3	24
373	Suppression of norepinephrine appearance rate in plasma by diazepam in humans. Life Sciences, 1988, 43, 1615-1623.	2.0	24
374	Short-Term Clarithromycin Administration Impairs Clearance and Enhances Pharmacodynamic Effects of Trazodone but Not of Zolpidem. Clinical Pharmacology and Therapeutics, 2009, 85, 644-650.	2.3	24
375	Determination of Desmethyldiazepam in Plasma by Electron-Capture GLC: Application to Pharmacokinetic Studies of Clorazepate. Journal of Pharmaceutical Sciences, 1978, 67, 427-429.	1.6	23
376	Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipotassium. Klinische Wochenschrift, 1982, 60, 411-415.	0.6	23
377	Diphenhydramine Determination in Human Plasma by Gas–Liquid Chromatography using Nitrogen–Phosphorus Detection: Application to Single Low-Dose Pharmacokinetic Studies. Journal of Pharmaceutical Sciences, 1983, 72, 941-943.	1.6	23
378	Interaction of Cimetidine with Oxazepam, Lorazepam, and Flurazepam. Journal of Clinical Pharmacology, 1984, 24, 187-193.	1.0	23

#	Article	IF	CITATIONS
379	Differential effects of chronic lorazepam and alprazolam on benzodiazepine binding and GABA _A â€receptor function. British Journal of Pharmacology, 1990, 101, 839-842.	2.7	23
380	Pharmacodynamic and receptor binding changes during chronic lorazepam administration. Pharmacology Biochemistry and Behavior, 2001, 69, 1-8.	1.3	23
381	Pharmacologic Consideration for the Use of Antiretroviral Agents in the Elderly. Journal of Clinical Pharmacology, 2008, 48, 1212-1225.	1.0	23
382	Isoniazid Mediates the <i>CYP2B6*6</i> Genotype-Dependent Interaction between Efavirenz and Antituberculosis Drug Therapy through Mechanism-Based Inactivation of CYP2A6. Antimicrobial Agents and Chemotherapy, 2014, 58, 4145-4152.	1.4	23
383	Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole. Journal of Clinical Psychopharmacology, 2018, 38, 289-295.	0.7	23
384	Effect of food on enteral absorption of quinidine. Clinical Pharmacology and Therapeutics, 1980, 27, 188-193.	2.3	22
385	Alcohol Does Not Enhance Diazepam Absorption. Pharmacology, 1981, 22, 263-268.	0.9	22
386	Chronic Treatment with Fluvoxamine, Clovoxamine, and Placebo: Interaction with Digoxin and Effects on Sleep and Alertness. Journal of Clinical Pharmacology, 1989, 29, 91-95.	1.0	22
387	Analysis of ritonavir in plasma/serum and tissues by high-performance liquid chromatography. Journal of Pharmacological and Toxicological Methods, 1998, 40, 235-239.	0.3	22
388	Human Pregnane X Receptor: Genetic Polymorphisms, Alternative mRNA Splice Variants, and Cytochrome P450 3A Metabolic Activity. Journal of Clinical Pharmacology, 2006, 46, 1356-1369.	1.0	22
389	Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin. Journal of Pharmacy and Pharmacology, 2010, 55, 1229-1239.	1.2	22
390	Adverse performance effects of acute lorazepam administration in elderly long-term users: Pharmacokinetic and clinical predictors. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 56, 129-135.	2.5	22
391	Use of Antipsychotics for the Treatment of Behavioral Symptoms of Dementia. Journal of Clinical Pharmacology, 2016, 56, 1048-1057.	1.0	22
392	Clinical Studies of Drug–Drug Interactions: Design and Interpretation. , 2010, , 625-649.		22
393	Self-rated sedation and plasma concentrations of desmethyldiazepam following single doses of clorazepate. Psychopharmacology, 1979, 66, 289-290.	1.5	21
394	Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. American Heart Journal, 1980, 99, 468-475.	1.2	21
395	Determination of zopiclone in plasma by liquid chromatography with application to steady-state monitoring. Biomedical Applications, 1986, 380, 211-215.	1.7	21
396	Gas chromatographic analysis of alprazolam in plasma: replicability, stability and specificity. Biomedical Applications, 1990, 534, 202-207.	1.7	21

#	Article	IF	CITATIONS
397	Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys. Psychopharmacology, 1991, 104, 103-105.	1.5	21
398	Modest but Variable Effect of Rifampin on Steady-State Plasma Pharmacokinetics of Efavirenz in Healthy African-American and Caucasian Volunteers. Antimicrobial Agents and Chemotherapy, 2011, 55, 3527-3533.	1.4	21
399	The ketoconazole legacy. Clinical Pharmacology in Drug Development, 2014, 3, 1-3.	0.8	21
400	The Pharmacovigilance Syndrome. Journal of Clinical Psychopharmacology, 2015, 35, 361-363.	0.7	21
401	Plasma and cerebrospinal fluid concentrations of chlordiazepoxide and its metabolites in surgical patients. Clinical Pharmacology and Therapeutics, 1976, 20, 571-578.	2.3	20
402	Accidental Iron Poisoning in Childhood. Clinical Pediatrics, 1976, 15, 835-838.	0.4	20
403	Electron-capture GLC determination of clobazam and desmethylclobazam in plasma. Journal of Pharmaceutical Sciences, 1980, 69, 1351-1352.	1.6	20
404	Plasma Levels of Trazodone: Methodology and Applications. Pharmacology, 1984, 28, 42-46.	0.9	20
405	Tissue Distribution of Diazepam and Its Metabolite Desmethyldiazepam: A Human Autopsy Study. Journal of Clinical Pharmacology, 1985, 25, 613-615.	1.0	20
406	Pharmacokinetics of intravenous caffeine: Comparison of high-performance liquid chromatographic and gas chromatographic methods. Biomedical Applications, 1987, 422, 274-280.	1.7	20
407	Lorazepam discontinuation promotes â€~inverse agonist' effects of benzodiazepines. British Journal of Pharmacology, 1989, 98, 451-454.	2.7	20
408	Modification of ?-Aminobutyric AcidAReceptor Binding and Function by N-Ethoxycarbonyl-2-Ethoxy-1,2-Dihydroquinoline In Vitro and In Vivo: Effects of Aging. Journal of Neurochemistry, 1991, 56, 1241-1247.	2.1	20
409	Benzodiazepine receptor binding of benzodiazepine hypnotics: Receptor and ligand specificity. Pharmacology Biochemistry and Behavior, 1992, 43, 413-416.	1.3	20
410	Effect of acute and chronic benzodiazepines on plasma GABA in anxious patients and controls. Psychopharmacology, 1992, 109, 153-156.	1.5	20
411	Differential Effect of Central versus Parenteral Administration of Morphine Sulf ate on Regional Concentrations of Reduced Glutathione in Rat Brain. Pharmacology, 1997, 54, 92-97.	0.9	20
412	Hypnotic Effects of Low Doses of Quazepam in Older Insomniacs. Journal of Clinical Psychopharmacology, 1997, 17, 401-406.	0.7	20
413	Single- and multiple-dose kinetics of intravenous digoxin. Clinical Pharmacology and Therapeutics, 1980, 28, 340-345.	2.3	19
414	Comparative Protein Binding of Diazepam and Desmethyldiazepam*. Journal of Clinical Pharmacology, 1981, 21, 219-223.	1.0	19

#	Article	IF	CITATIONS
415	Improved liquid chromatographic analysis of phenytoin and salicylate using radial compression separation. Biomedical Applications, 1983, 275, 450-457.	1.7	19
416	Comparative Singleâ€Đose Kinetics of Oxazolam, Prazepam, and Clorazepate: Three Precursors of Desmethyldiazepam. Journal of Clinical Pharmacology, 1984, 24, 446-451.	1.0	19
417	Effect of cimetidine on digoxin kinetics and creatinine clearance. American Heart Journal, 1984, 107, 170-172.	1.2	19
418	Studies With Stable Isotopes I: Changes in Phenytoin Pharmacokinetics and Biotransformation During Monotherapy. Journal of Clinical Pharmacology, 1985, 25, 43-50.	1.0	19
419	Differential modulation of benzodiazepine receptor binding by ethanol in LS and SS mice. Pharmacology Biochemistry and Behavior, 1988, 29, 471-477.	1.3	19
420	Triazolam Kinetics: Interaction with Cimetidine, Propranolol, and the Combination. Journal of Clinical Pharmacology, 1988, 28, 228-233.	1.0	19
421	Doxylamine and Diphenhydramine Pharmacokinetics in Women on Lowâ€Dose Estrogen Oral Contraceptives. Journal of Clinical Pharmacology, 1989, 29, 257-260.	1.0	19
422	Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. Biopharmaceutics and Drug Disposition, 1990, 11, 185-189.	1.1	19
423	Imipramine and Buspirone in Patients With Panic Disorder Who Are Discontinuing Long-term Benzodiazepine Therapy. Journal of Clinical Psychopharmacology, 2003, 23, 505-508.	0.7	19
424	Chapter 11. The CYP3 Family. Issues in Toxicology, 2008, , 354-383.	0.2	19
425	Zolpidem Pharmacokinetic Properties in Young Females: Influence of Smoking and Oral Contraceptive Use. Journal of Clinical Pharmacology, 2002, 42, 1142-1146.	1.0	19
426	Sex Differences in Diazepam Protein Binding in Patients with Renal Insufficiency. Pharmacology, 1978, 16, 26-29.	0.9	18
427	Drug toxicity in patients receiving digoxin and quinidine. American Heart Journal, 1983, 105, 1025-1028.	1.2	18
428	Benzodiazepine drug-drug interactions commonly occurring in clinical practice. Current Medical Research and Opinion, 1984, 8, 80-93.	0.9	18
429	Pharmacokinetic Noninteraction of Triazolam and Ethanol. Journal of Clinical Psychopharmacology, 1984, 4, 106-107.	0.7	18
430	Differential Effects of Isoniazid and Oral Contraceptive Steroids on Antipyrine Oxidation and Acetaminophen Conjugation. Pharmacology, 1984, 28, 188-195.	0.9	18
431	Tyr-MIF-1 augments benzodiazepine receptor binding in vivo. Pharmacology Biochemistry and Behavior, 1987, 28, 521-524.	1.3	18
432	Therapeutic serum lidocaine and metabolite concentrations in patients undergoing electrophysiologic study after discontinuation of intravenous lidocaine infusion. American Heart Journal, 1989, 117, 1060-1064.	1.2	18

#	Article	IF	CITATIONS
433	Validity of Selfâ€Reports of Caffeine Use. Journal of Clinical Pharmacology, 1991, 31, 677-680.	1.0	18
434	Propofol Clearance and Volume of Distribution Are Increased in Patients With Major Burns. Journal of Clinical Pharmacology, 2009, 49, 768-772.	1.0	18
435	Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1609-1618.	1.5	18
436	Antidepressant-Associated Hyponatremia in the Elderly. Journal of Clinical Psychopharmacology, 2016, 36, 545-549.	0.7	18
437	Mechanisms and Consequences of Drugâ€Ðrug Interactions. Clinical Pharmacology in Drug Development, 2017, 6, 118-124.	0.8	18
438	Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes. Drug Metabolism and Disposition, 2017, 45, 1035-1043.	1.7	18
439	A Comparative Pharmacokinetic and Dynamic Evaluation of Alprazolam Sustained-Release, Bromazepam, and Lorazepam. Journal of Clinical Psychopharmacology, 2000, 20, 628-635.	0.7	18
440	Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. Journal of Clinical Pharmacology, 2002, 42, 376-82.	1.0	18
441	Serum Creatine Phosphokinase Concentrations After Intramuscular Chlordiazepoxide and Its Solvent. Journal of Clinical Pharmacology, 1976, 16, 118-121.	1.0	17
442	Clinical Effects of Chloral Hydrate in Hospitalized Medical Patients Journal of Clinical Pharmacology, 1979, 19, 669-674.	1.0	17
443	Disease-related Alterations in Cardiac Glycoside Disposition. Clinical Pharmacokinetics, 1982, 7, 434-451.	1.6	17
444	Noninteraction of Temazepam and Cimetidine. Journal of Pharmaceutical Sciences, 1984, 73, 399-401.	1.6	17
445	Haloperidol determination in serum and cerebrospinal fluid using gas—liquid chromatography with nitrogen—phosphorus detection: Application to pharmacokinetic studies. Biomedical Applications, 1984, 307, 194-199.	1.7	17
446	More Than Skin Deep: Transdermal Drug-Delivery Systems. New England Journal of Medicine, 1986, 314, 1638-1639.	13.9	17
447	High-Affinity Benzodiazepine Binding Sites on Rat Peritoneal Mast Cells and RBL-1 Cells: Binding Characteristics and Effects on Granule Secretion. Pharmacology, 1988, 36, 52-60.	0.9	17
448	Intramuscular Haloperidol or Lorazepam and QT Intervals in Schizophrenia. Journal of Clinical Pharmacology, 2004, 44, 1173-1184.	1.0	17
449	Acute zolpidem administration produces pharmacodynamic and receptor occupancy changes at similar doses. Pharmacology Biochemistry and Behavior, 2006, 83, 21-27.	1.3	17
450	The Prescription of Benzodiazepines for Panic Disorder. Journal of Clinical Psychopharmacology, 2018, 38, 283-285.	0.7	17

#	Article	IF	CITATIONS
451	Clozapine and Fluvoxamine, a Curious Complexity. Journal of Clinical Psychopharmacology, 1998, 18, 101-102.	0.7	17
452	Comparison of one- and six-day urinary digoxin excretion in single-dose bioavailability studies. Clinical Pharmacology and Therapeutics, 1974, 16, 813-816.	2.3	16
453	Factors influencing blood concentrations of chlordiazepoxide: A use of multiple regression analysis. Psychopharmacology, 1977, 54, 277-282.	1.5	16
454	Overdosage with Pentobarbital and Secobarbital: Assessment of Factors Related to Outcome. Journal of Clinical Pharmacology, 1979, 19, 758-768.	1.0	16
455	Effect of Magnesium—Aluminum Hydroxide and Kaolin—Pectin on Absorption of Digoxin from Tablets and Capsules. Journal of Clinical Pharmacology, 1981, 21, 26-30.	1.0	16
456	A pharmacokinetic study of CGS-8216, a benzodiazepine receptor ligand, in the rat. Psychopharmacology, 1984, 84, 420-422.	1.5	16
457	Absolute Bioavailability and Effect of Food and Antacid on Diazepam Absorption from a Slowâ€Release Preparation. Journal of Clinical Pharmacology, 1984, 24, 255-263.	1.0	16
458	Differential Effect of Cigarette Smoking on Antipyrine Oxidation versus Acetaminophen Conjugation. Pharmacology, 1990, 40, 77-84.	0.9	16
459	Presystemic Extraction: Mechanisms and Consequences. Journal of Clinical Pharmacology, 1993, 33, 650-656.	1.0	16
460	Effects of diphenhydramine on human eye movements. Psychopharmacology, 1995, 118, 280-286.	1.5	16
461	Influence of Polyethylene Glycol and Acetone on the in Vitro Biotransformation of Tamoxifen and Alprazolam by Human Liver Microsomes. Journal of Pharmaceutical Sciences, 1996, 85, 1180-1185.	1.6	16
462	Hyperforin Plasma Level as a Marker of Treatment Adherence in the National Institutes of Health Hypericum Depression Trial. Journal of Clinical Psychopharmacology, 2005, 25, 243-249.	0.7	16
463	In Vitro Prediction of Clinical Drug Interactions With CYP3A Substrates: We Are Not There Yet. Clinical Pharmacology and Therapeutics, 2014, 95, 133-135.	2.3	16
464	Nefazodone in Major Depression. Journal of Clinical Psychopharmacology, 1998, 18, 145-153.	0.7	16
465	Potassium, Antipsychotic Agents, Arrhythmias, and Sudden Death. Journal of Clinical Psychopharmacology, 1998, 18, 427-428.	0.7	16
466	A reevaluation of intravenous quinidine. American Heart Journal, 1978, 96, 829-832.	1.2	15
467	KINETICS OF HIGH-DOSE I.V. DIAZEPAM. British Journal of Anaesthesia, 1982, 54, 849-852.	1.5	15
468	Liquid Chromatographic Determination of Chlordiazepoxide and Metabolites in Plasma. Pharmacology, 1982, 24, 261-266.	0.9	15

#	Article	IF	CITATIONS
469	Simultaneous determination of lidocaine and its deethylated metabolites using gas—liquid chromatography with nitrogen—phosphorus detection. Biomedical Applications, 1984, 307, 200-205.	1.7	15
470	Studies With Stable Isotopes III: Pharmacokinetics of Tracer Doses of Drug. Journal of Clinical Pharmacology, 1985, 25, 59-63.	1.0	15
471	Chronic benzodiazepine administration. Psychopharmacology, 1993, 111, 91-95.	1.5	15
472	Chronic Benzodiazepine Administration XI Concurrent Administration of PK11195 Attenuates Lorazepam Discontinuation Effects. Neuropsychopharmacology, 1993, 8, 267-273.	2.8	15
473	Apparent active transport of MDMA is not mediated by P-glycoprotein: a comparison with MDCK and Caco-2 monolayers. Biopharmaceutics and Drug Disposition, 2006, 27, 219-227.	1.1	15
474	Antiretroviral boosting by cobicistat, a structural analog of ritonavir. Clinical Pharmacology in Drug Development, 2014, 3, 335-337.	0.8	15
475	Characterization of cognitive dysfunction in Sjögren's syndrome patients. Clinical Rheumatology, 2014, 33, 511-521.	1.0	15
476	Vortioxetine Disposition in Obesity. Journal of Clinical Psychopharmacology, 2018, 38, 172-179.	0.7	15
477	Newer Antidepressants. Journal of Clinical Psychopharmacology, 1997, 17, 1-3.	0.7	15
478	Differences in Pharmacodynamics but Not Pharmacokinetics Between Subjects With Panic Disorder and Healthy Subjects After Treatment With a Single Dose of Alprazolam. Journal of Clinical Psychopharmacology, 2000, 20, 338-346.	0.7	15
479	Effect of alprazolam on digoxin kinetics and creatinine clearance. Clinical Pharmacology and Therapeutics, 1985, 38, 595-598.	2.3	14
480	Measurement of Clonazepam by Electron-Capture Gas-Liquid Chromatography with Application to Single-Dose Pharmacokinetics. Journal of Analytical Toxicology, 1987, 11, 55-57.	1.7	14
481	Bioinequivalence of a generic brand of diazepam. Biopharmaceutics and Drug Disposition, 1989, 10, 597-605.	1.1	14
482	Chronic alcohol abuse and the acute sedative and neurophysiologic effects of midazolam. Psychopharmacology, 1997, 133, 293-299.	1.5	14
483	Molecular and Pharmacokinetic Evaluation of Rat Hepatic and Gastrointestinal Cytochrome P450 Induction by Tamoxifen. Pharmacology, 2001, 63, 210-219.	0.9	14
484	Interdose Elevation in Plasma Cortisol During Chronic Treatment with Alprazolam but not Lorazepam in the Elderly. Neuropsychopharmacology, 2004, 29, 605-611.	2.8	14
485	Liquid chromatographic retention of \hat{l}^2 -adrenoceptor antagonists: an index of lipid solubility. Journal of Pharmacy and Pharmacology, 2011, 36, 400-401.	1.2	14
486	Mechanism-based inhibition of human Cytochrome P450-3A activity by grapefruit hybrids having low furanocoumarin content. Xenobiotica, 2012, 42, 1163-1169.	0.5	14

#	Article	IF	CITATIONS
487	Effect of blueberry juice on clearance of buspirone and flurbiprofen in human volunteers. British Journal of Clinical Pharmacology, 2013, 75, 1041-1052.	1.1	14
488	Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis. Journal of Clinical Pharmacology, 2014, 54, 1180-1187.	1.0	14
489	Persistence of a Posaconazoleâ€Mediated Drugâ€Drug Interaction With Ranolazine After Cessation of Posaconazole Administration: Impact of Obesity and Implications for Patient Safety. Journal of Clinical Pharmacology, 2018, 58, 1436-1442.	1.0	14
490	Methadone Disposition: Implementing Lessons Learned. Journal of Clinical Pharmacology, 2019, 59, 1044-1048.	1.0	14
491	The Reappearance of a Monamine Oxidase Inhibitor (Isocarboxazid). Journal of Clinical Psychopharmacology, 1999, 19, 105-106.	0.7	14
492	Absorption of oral tetracycline in patients with Billroth-II gastrectomy. Journal of Pharmacokinetics and Pharmacodynamics, 1978, 6, 295-303.	0.6	13
493	Effects of desmethyldiazepam on diazepam kinetics: A study of effects of a metabolite on parent drug disposition. Clinical Pharmacology and Therapeutics, 1981, 29, 757-761.	2.3	13
494	Determination of Ro 15-1788, a Benzodiazepine Antagonist, in Human Plasma by Gas-Liquid Chromatography with Nitrogen-Phosphorus Detection. Pharmacology, 1983, 26, 285-289.	0.9	13
495	Is Temazepam an Accumulating Hypnotic?. Journal of Clinical Pharmacology, 1984, 24, 58-64.	1.0	13
496	Lack of Effect of Influenza Vaccine on the Pharmacokinetics of Antipyrine, Alprazolam, Paracetamol (Acetaminophen) and Lorazepam. Clinical Pharmacokinetics, 1989, 16, 180-185.	1.6	13
497	Separate and combined effects of caffeine and alprazolam on motor activity and benzodiazepine receptor binding in vivo. Psychopharmacology, 1990, 101, 539-544.	1.5	13
498	Augmentation of GABAA receptor function by chronic exposure to GABA-neutral and GABA-negative benzodiazepine ligands in cultured cortical neurons. Biochemical Pharmacology, 1990, 40, 1337-1344.	2.0	13
499	Drug interactions with methadone: Time to revise the product label. Clinical Pharmacology in Drug Development, 2014, 3, 249-251.	0.8	13
500	Meldonium (Mildronate): A Performanceâ€Enhancing Drug?. Clinical Pharmacology in Drug Development, 2016, 5, 167-169.	0.8	13
501	<i>In vitro</i> inhibition of human UGT isoforms by ritonavir and cobicistat. Xenobiotica, 2018, 48, 764-769.	0.5	13
502	Evidence for Systematic Temporal Variation In 24â€Hour Urinary Creatinine Excretion. Journal of Clinical Pharmacology, 1977, 17, 108-119.	1.0	12
503	Singleâ€Dose Kinetics of Prazepam, a Precursor of Desmethyldiazepam. Journal of Clinical Pharmacology, 1979, 19, 445-450.	1.0	12
504	Binding of diazepam and desmethyldiazepam to plasma protein: Concentration-dependence and interactions. Psychopharmacology, 1981, 75, 380-382.	1.5	12

#	Article	IF	CITATIONS
505	Pilot Pharmacokinetic Study of Brotizolam, a Thienodiazepine Hypnotic, Using Electron-Capture Gas-Liquid Chromatography. Sleep, 1983, 6, 72-76.	0.6	12
506	Rapid high-performance liquid chromatographic analysis of oxaprozin, a non-steroidal anti-inflammatory agent. Biomedical Applications, 1984, 310, 445-449.	1.7	12
507	Differential Side Effect Profile of Triazolam Versus Flurazepam in Elderly Patients Undergoing Rehabilitation Therapy. Journal of Clinical Pharmacology, 1991, 31, 168-173.	1.0	12
508	Kinetic-Dynamic Modeling in Clinical. Journal of Clinical Psychopharmacology, 1993, 13, 231???234.	0.7	12
509	Influence of Oral Contraceptive Use and Cigarette Smoking, Alone and Together, on Antipyrine Pharmacokinetics. Journal of Clinical Pharmacology, 1997, 37, 437-441.	1.0	12
510	The Influence of the Menstrual Cycle on Triazolam and Indocyanine Green Pharmacokinetics. Journal of Clinical Pharmacology, 2000, 40, 739-744.	1.0	12
511	THE EFFECT OF AGE ON SILDENAFIL BIOTRANSFORMATION IN RAT AND MOUSE LIVER MICROSOMES. Drug Metabolism and Disposition, 2003, 31, 1306-1309.	1.7	12
512	Clonazepam Pharmacokinetics: Comparison of Subcutaneous Microsphere Injection With Multiple-Dose Oral Administration. Journal of Clinical Pharmacology, 2005, 45, 1288-1293.	1.0	12
513	Phenacetin and chlorzoxazone biotransformation in aging male Fischer 344 rats. Journal of Pharmacy and Pharmacology, 2010, 56, 819-825.	1.2	12
514	Pharmacokinetics of Zolpidem from Sublingual Zolpidem Tartrate Tablets In Healthy Elderly Versus Non-Elderly Subjects. Drugs and Aging, 2014, 31, 731-736.	1.3	12
515	Ketoconazoleâ€Associated Liver Injury in Drugâ€Drug Interaction Studies in Healthy Volunteers. Journal of Clinical Pharmacology, 2016, 56, 1196-1202.	1.0	12
516	Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. Journal of Pharmacy and Pharmacology, 2019, 71, 982-987.	1.2	12
517	Twice May Be Too Many. Journal of Clinical Psychopharmacology, 1996, 16, 1-2.	0.7	12
518	Appetite Suppressant Drugs as Inhibitors of Human Cytochromes P450. Journal of Clinical Psychopharmacology, 1998, 18, 338-341.	0.7	12
519	Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques. Journal of Clinical Pharmacology, 2002, 42, 376-382.	1.0	12
520	Drug Disposition in Subjects With Obesity: The Research Work of Darrell R. Abernethy. Journal of Clinical Pharmacology, 2022, 62, 1350-1363.	1.0	12
521	Assessment of Methodology in Single-Dose Studies of Digoxin Bioavailability. Pharmacology, 1976, 14, 182-190.	0.9	11
522	Clinical Pharmacokinetics of Lorazepam. IV. Longâ€Term Oral Administration. Journal of Clinical Pharmacology, 1977, 17, 495-500.	1.0	11

#	Article	IF	CITATIONS
523	Adverse reactions to practolol in hospitalized patients. European Journal of Clinical Pharmacology, 1977, 12, 167-170.	0.8	11
524	Effect of Abdominal Radiation Therapy on Drug Absorption in Humans. Journal of Clinical Pharmacology, 1978, 18, 388-396.	1.0	11
525	Automated Electron-Capture Gas Chromatographic Analysis of Flunitrazepam in Plasma. Pharmacology, 1982, 24, 82-87.	0.9	11
526	Kinetics and cardiac effects of propranolol in humans. Klinische Wochenschrift, 1982, 60, 521-525.	0.6	11
527	Antipyretic analgesic drugs as models for studies of drug disposition in old age. American Journal of Medicine, 1983, 75, 127-132.	0.6	11
528	Reduced Distribution and Clearance of Acetaminophen in Patients with Congestive Heart Failure. Journal of Cardiovascular Pharmacology, 1983, 5, 697-699.	0.8	11
529	Doseâ€Independent Pharmacokinetics of Intravenous Lidocaine in Humans. Journal of Clinical Pharmacology, 1983, 23, 186-188.	1.0	11
530	Ibuprofen kinetics in patients with renal insufficiency who are receiving maintenance hemodialysis. Arthritis and Rheumatism, 1985, 28, 1430-1434.	6.7	11
531	Pharmacologic properties of acebutolol: Relationship of hydrophilicity to central nervous system penetration. American Heart Journal, 1985, 109, 1120-1125.	1.2	11
532	Large Theophylline Requirements due to High Theophylline Clearance: Verification by the Antipyrine Test. Pharmacology, 1986, 32, 226-231.	0.9	11
533	Effect of Diazepam on Plasma gamma-Aminobutyric Acid in Sons of Alcoholic Fathers. Alcoholism: Clinical and Experimental Research, 1996, 20, 343-347.	1.4	11
534	Human cytochromes mediating gepirone biotransformation at low substrate concentrations. Biopharmaceutics and Drug Disposition, 2003, 24, 87-94.	1.1	11
535	Preparation of Scientific Reports on Pharmacokinetic Drug Interaction Studies. Journal of Clinical Psychopharmacology, 2008, 28, 369-373.	0.7	11
536	Hepatic Clearance of Drugs in Patients With Renal Insufficiency. Clinical Pharmacology in Drug Development, 2013, 2, 295-297.	0.8	11
537	Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. Clinical Therapeutics, 2018, 40, 64-73.	1.1	11
538	Mechanisms and Consequences of Drug-Drug Interactions. , 0, , 879-917.		11
539	Treatment, Discontinuation, and Psychomotor Effects of Diazepam in Women With Generalized Anxiety Disorder. Journal of Clinical Psychopharmacology, 1996, 16, 202-207.	0.7	11
540	Serum Digoxin Concentrations and Subjective Manifestations of Toxicity. Pharmacology, 1980, 20, 149-154.	0.9	11

#	Article	IF	CITATIONS
541	Drug interactions involving psychotropic drugs. Psychosomatics, 1978, 19, 671-681.	2.5	10
542	Steady-state plasma desmethyldiazepam during long-term clorazepate use: Effect of antacids. Clinical Pharmacology and Therapeutics, 1982, 31, 180-183.	2.3	10
543	Lorazepam Attenuates the Behavioral Effects of Dizocilpine. Pharmacology Biochemistry and Behavior, 1999, 62, 103-110.	1.3	10
544	Evaluation of SupermixTM as anin vitro model of human liver microsomal drug metabolism. Biopharmaceutics and Drug Disposition, 2002, 23, 183-190.	1.1	10
545	Translocase of Outer Mitochondrial Membrane 40 Homolog (TOMM40) Poly-T Length Modulates Lorazepam-Related Cognitive Toxicity in Healthy APOE ε4-Negative Elderly. Journal of Clinical Psychopharmacology, 2011, 31, 544-546.	0.7	10
546	Pharmacokinetics and Pharmacodynamics for Medical Students: A Proposed Course Outline. Journal of Clinical Pharmacology, 2016, 56, 1180-1195.	1.0	10
547	Question the Experts. Journal of Clinical Psychopharmacology, 1997, 17, 331.	0.7	10
548	ApoE-epsilon4 Allele and Susceptibility to Drug-Induced Memory Impairment in the Elderly. Journal of Clinical Psychopharmacology, 1998, 18, 179-181.	0.7	10
549	Drug Transporters in Psychopharmacology-Are They Important?. Journal of Clinical Psychopharmacology, 2000, 20, 291-294.	0.7	10
550	Which Drug for Alcohol Withdrawal?. The Journal of Clinical Pharmacology and New Drugs, 1972, 12, 429-431.	0.3	9
551	Chlorpromazine and Hyperpyrexia. Clinical Pediatrics, 1973, 12, 504-505.	0.4	9
552	Comparative Protein Binding of Diazepam and Desmethyldiazepam. Journal of Clinical Pharmacology, 1980, 20, 639-643.	1.0	9
553	Kinetics of Oxazepam and Lorazepam in Two Subjects with Gilbert Syndrome*. Journal of Clinical Psychopharmacology, 1981, 1, 400-402.	0.7	9
554	Halazepam as a precursor of desmethyldiazepam: Quantitation by electron-capture gas-liquid chromatography. Psychopharmacology, 1983, 80, 178-180.	1.5	9
555	Cyclosporine Blood Concentrations Determined by Specific Versus Nonspecific Assay Methods. Journal of Clinical Pharmacology, 1986, 26, 367-371.	1.0	9
556	Determination of ciramadol and dezocine, two new analgesics, by high-performance liquid chromatography using electrochemical detection. Biomedical Applications, 1986, 374, 215-220.	1.7	9
557	New Pharmacokinetic Methods III. Two Simple Tests for "Deep Pool Effect― Journal of Clinical Pharmacology, 1990, 30, 680-685.	1.0	9
558	Drug Transporters Revisited. Journal of Clinical Psychopharmacology, 2001, 21, 1-3.	0.7	9

#	Article	IF	CITATIONS
559	Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance. Psychopharmacology, 2005, 182, 414-419.	1.5	9
560	Dose-dependent retrograde facilitation of verbal memory in healthy elderly after acute oral lorazepam administration. Psychopharmacology, 2006, 185, 487-494.	1.5	9
561	Therapeutic Drug Monitoring of Antidepressants. Handbook of Experimental Pharmacology, 2018, 250, 115-133.	0.9	9
562	Slow Accumulation and Elimination of Diazepam and Its Active Metabolite With Extended Treatment in the Elderly. Journal of Clinical Pharmacology, 2021, 61, 193-203.	1.0	9
563	Clinical Pharmacology and Therapeuticsof Antidepressants. , 2011, , 33-124.		9
564	Ritonavir induces Pâ€glycoprotein expression, multidrug resistanceâ€associated protein (MRP1) expression, and drug transporterâ€mediated activity in a human intestinal cell line. Journal of Pharmaceutical Sciences, 2001, 90, 1829-1837.	1.6	9
565	Role of Nurse and Pharmacist Monitors in the Boston Collaborative Drug Surveillance Program. Drug Intelligence & Clinical Pharmacy, 1975, 9, 648-654.	0.4	8
566	Cerebrospinal Fluid Digoxin Concentrations in Humans. Journal of Clinical Pharmacology, 1978, 18, 16-20.	1.0	8
567	Pharmacokinetics: Doseâ€Dependent Changes. Journal of Clinical Pharmacology, 1986, 26, 463-468.	1.0	8
568	Pharmacokinetics of oxaprozin and other nonsteroidal antiinflammatory agents. Seminars in Arthritis and Rheumatism, 1986, 15, 18-26.	1.6	8
569	Poor bioavailability of CCS 8216 in a water/tween vehicle following intraperitoneal injection. Psychopharmacology, 1987, 91, 260-1.	1.5	8
570	Antipyrine Pharmacokinetics in Women Receiving Conjugated Estrogens. Journal of Clinical Pharmacology, 1988, 28, 463-466.	1.0	8
571	Reduced Systemic Absorption of Intrabronchial Lidocaine by Highâ€Frequency Nebulization. Journal of Clinical Pharmacology, 1990, 30, 795-797.	1.0	8
572	In situ hybridization histochemistry as a method to assess GABAAreceptor subunit mRNA expression following chronic alprazolam administration. Journal of Psychopharmacology, 1999, 13, 211-218.	2.0	8
573	Drug-Drug Interactions, Second Edition. , 0, , .		8
574	Drug–Drug Noninteractions. Cardiovascular Therapeutics, 2009, 27, 226-229.	1.1	8
575	Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets. Journal of Clinical Pharmacology, 2013, 53, 1194-1198.	1.0	8
576	Body Size Changes Among National Collegiate Athletic Association New England Division III Football Players, 1956â''2014: Comparison With Age-Matched Population Controls. Journal of Athletic Training, 2016, 51, 373-381.	0.9	8

#	Article	IF	CITATIONS
577	Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir. Journal of Pharmacy and Pharmacology, 2017, 69, 1794-1801.	1.2	8
578	Ketoconazole and Liver Injury: A Five‥ear Update. Clinical Pharmacology in Drug Development, 2019, 8, 6-8.	0.8	8
579	Pharmacokinetic Determinants of the Clinical Effects of Benzodiazepine Agonist Hypnotics. , 2010, , 95-118.		8
580	Lack of Effect of Sertraline on the Pharmacokinetics of Alprazolam. Journal of Clinical Psychopharmacology, 2000, 20, 585-586.	0.7	8
581	Cognitive toxicity of drugs used in the elderly. Dialogues in Clinical Neuroscience, 2001, 3, 181-190.	1.8	8
582	Pharmacokinetic Determinants of the Response to Single Doses of Chlordiazepoxide. American Journal of Psychiatry, 1974, 131, 1395-1397.	4.0	7
583	Problems with Drug Interactions in Treating Brain Disorders. Psychiatric Clinics of North America, 1978, 1, 51-69.	0.7	7
584	Effect of Ketanserin on the Kinetics of Digoxin and Digitoxin. Journal of Cardiovascular Pharmacology, 1985, 7, 205-207.	0.8	7
585	Simplified gas chromatographic assay of underivatized nitrazepam in plasma. Biomedical Applications, 1985, 337, 131-135.	1.7	7
586	Antipyrine and Lidocaine Are Cleared Faster in Horses than in Humans: Acetaminophen May Be Handled Similarly. Pharmacology, 1987, 34, 192-200.	0.9	7
587	Drug Absorption Rate: A Critical Component of Bioequivalence Assessment in Psychopharmacology. Journal of Clinical Pharmacology, 1987, 27, 85-86.	1.0	7
588	Benzodiazepine Receptor Binding Response to Acute and Chronic Stress Is Increased in Aging Animals. Pharmacology, 1991, 42, 181-187.	0.9	7
589	Analysis of generic antiretroviral formulations manufactured in India. Aids, 2004, 18, 1482-1484.	1.0	7
590	Pharmacologic Management of Dental Anxiety. Journal of Clinical Psychopharmacology, 2006, 26, 1-3.	0.7	7
591	The effect of chronic lorazepam administration in aging mice. Brain Research, 2006, 1118, 13-24.	1.1	7
592	Relationship Between Plasma Protease Inhibitor Concentrations and Lipid Elevations in HIV Patients on a Doubleâ€Boosted Protease Inhibitor Regimen (Saquinavir/Lopinavir/Ritonavir). Journal of Clinical Pharmacology, 2010, 50, 392-400.	1.0	7
593	Preclinical rodent toxicity studies for long term use of ceftriaxone. Toxicology Reports, 2015, 2, 1396-1403.	1.6	7
594	Inhibition of 2-methoxyestradiol glucuronidation by probenecid. Journal of Pharmacy and Pharmacology, 2015, 67, 1585-1592.	1.2	7

#	Article	IF	CITATIONS
595	Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. Journal of Pharmacy and Pharmacology, 2016, 69, 82-88.	1.2	7
596	The Importance of Presystemic Extraction in Clinical Psychopharmacology. Journal of Clinical Psychopharmacology, 1996, 16, 417-419.	0.7	7
597	More on Oral Contraceptives, Drug Interactions, Herbal Medicines, and Hormone Replacement Therapy. Journal of Clinical Psychopharmacology, 2000, 20, 397-398.	0.7	7
598	Selective Serotonin Reuptake Inhibitor Antidepressants: Cardiovascular Complications—Sorting Through Findings. Journal of Clinical Psychopharmacology, 2001, 21, 467-468.	0.7	7
599	Diazepam in the Elderly: Looking Back, Ahead, and at the Evidence. Journal of Clinical Psychopharmacology, 2020, 40, 215-219.	0.7	7
600	Rational use of psychotropic drugs. I. Hypnotics. American Journal of Health-System Pharmacy, 1974, 31, 990-1000.	0.5	6
601	Neuropsychiatric Sequelae of Pharmacotherapy of Cardiac Arrhythmias and Hypertension. Journal of Clinical Psychopharmacology, 1981, 1, 394-398.	0.7	6
602	Evaluation of the Hypothalamic—Pituitary Effects of Digoxin. Journal of Clinical Pharmacology, 1984, 24, 474-479.	1.0	6
603	The Admissibility of Positive EMIT Results as Scientific Evidence Counting Facts, Not Heads. Journal of Clinical Psychopharmacology, 1985, 5, 114-116.	0.7	6
604	Benzodiazepine binding sites on PC12 cells: Modulation by nerve growth factor and forskolin. Neuroscience Letters, 1988, 89, 342-348.	1.0	6
605	Prenatal benzodiazepine administration. II. Lorazepam exposure is associated with decreases in [35S]TBPS binding but not benzodiazepine binding. Pharmacology Biochemistry and Behavior, 1991, 40, 429-432.	1.3	6
606	Antipyrine Kinetics in Patients with Primary Biliary Cirrhosis. Journal of Clinical Pharmacology, 1993, 33, 75-78.	1.0	6
607	ALPRAZOLAM HYDROXYLATION BY MOUSE LIVER MICROSOMESIN VITRO: THE EFFECT OF AGE AND PHENOBARBITAL INDUCTION. , 1997, 18, 139-149.		6
608	The Maturation of Clinical Pharmacology: Recognizing the Contributions of Dr. Louis Lasagna. Journal of Clinical Pharmacology, 1998, 38, 572-574.	1.0	6
609	Pharmacokinetics and electroencephalographic effects of ketoconazole in the rat. , 1999, 20, 49-52.		6
610	A BENZODIAZEPINE MOOD EFFECT SCALE: RELIABILITY AND VALIDITY DETERMINED FOR ALCOHOL-DEPENDENT SUBJECTS AND ADULTS WITH A PARENTAL HISTORY OF ALCOHOLISM. American Journal of Drug and Alcohol Abuse, 2001, 27, 339-347.	1.1	6
611	Effects of Acute Lorazepam Administration on Aminergic Activity in Normal Elderly Subjects: Relationship to Performance Effects and Apolipoprotein Genotype. Neurochemical Research, 2004, 29, 1391-1398.	1.6	6
612	Into the Second Year. Clinical Pharmacology in Drug Development, 2013, 2, 1-1.	0.8	6

#	Article	IF	CITATIONS
613	Stereoâ€Psychopharmacology: The Case of Citalopram and Escitalopram. Clinical Pharmacology in Drug Development, 2016, 5, 331-335.	0.8	6
614	Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	6
615	Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment. Journal of Clinical Pharmacology, 2022, 62, 55-65.	1.0	6
616	Clinical Pharmacology and Therapeutics of Antidepressants. , 2004, , 33-117.		6
617	Introduction to Drug-Drug Interactions. , 2011, , 1-10.		6
618	Protease Inhibitors and Drug Interactions-An Alert. Journal of Clinical Psychopharmacology, 1996, 16, 343-344.	0.7	6
619	Benzodiazepines: Some Aspects of Their Clinical Pharmacology. Novartis Foundation Symposium, 1980, , 141-155.	1.2	6
620	Magnesium pemoline and iob performance in mentally handicapped workers. Clinical Pharmacology and Therapeutics, 1969, 10, 530-533.	2.3	5
621	Intravenous digoxin as a bioavailability standard. Clinical Pharmacology and Therapeutics, 1975, 17, 117-119.	2.3	5
622	Metoprolol or Propranolol Does Not Alter the Kinetics of Procainamide. Journal of Cardiovascular Pharmacology, 1983, 5, 392-395.	0.8	5
623	Staggered Stable Isotope Administration Technique for Study of Drug Distribution. Journal of Clinical Pharmacology, 1985, 25, 309-312.	1.0	5
624	The interactions of propranolol and ketanserin. Clinical Pharmacology and Therapeutics, 1987, 41, 55-60.	2.3	5
625	Accelerated benzodiazepine receptor recovery after lorazepam discontinuation. FASEB Journal, 1991, 5, 93-97.	0.2	5
626	Contribution of the Gastrointestinal Tract to Lorazepam Conjugation and Clonazepam Nitroreduction. Pharmacology, 1991, 42, 36-48.	0.9	5
627	Unusually Low Clearance of Two CYP3A Substrates, Alprazolam and Trazodone, in a Volunteer Subject with Wild-Type CYP3A4 Promoter Region. Journal of Clinical Pharmacology, 2000, 40, 200-204.	1.0	5
628	Drug Interaction Studies With CYP3A Substrates: How Much Inhibitor Pre-exposure Is Needed?. Clinical Pharmacology in Drug Development, 2012, 1, 83-84.	0.8	5
629	Sleepâ€promoting medications: Weighing the hazards of use versus nonâ€use. Clinical Pharmacology in Drug Development, 2014, 3, 167-169.	0.8	5
630	Volume of distribution – Again. Clinical Pharmacology in Drug Development, 2014, 3, 419-420.	0.8	5

#	Article	IF	CITATIONS
631	The Impact Non-Factor. Journal of Clinical Psychopharmacology, 2017, 37, 389-390.	0.7	5
632	Erythromycin acts through the ghrelin receptor to attenuate inflammatory responses in chondrocytes and maintain joint integrity. Biochemical Pharmacology, 2019, 165, 79-90.	2.0	5
633	Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations. Journal of Clinical Pharmacology, 2022, 62, 66-75.	1.0	5
634	More on Drugs and Pregnancy. Journal of Clinical Psychopharmacology, 1995, 15, 1-2.	0.7	5
635	Fruit Juices and Pharmacology. Journal of Clinical Psychopharmacology, 1997, 17, 245-246.	0.7	5
636	Conflicts of Interest, Redundant Publication, and Identification of Authorship. Journal of Clinical Psychopharmacology, 1998, 18, 183-184.	0.7	5
637	Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware. Journal of Clinical Pharmacology, 2022, 62, 925-927.	1.0	5
638	Chlordiazepoxide Metabolism in Mice following Hepatic Irradiation. Pharmacology, 1975, 13, 248-251.	0.9	4
639	The Pharmacokinetization of Psychiatry. Journal of Clinical Pharmacology, 1985, 25, 239-240.	1.0	4
640	Estimation of the Elimination Halfâ€Life of a Drug at Any Serum Concentration When the K _m and V _{max} of the Drug Are Known: Calculations and Validation With Phenytoin. Journal of Clinical Pharmacology, 1987, 27, 318-320.	1.0	4
641	Pharmacokinetics and CSF Entry of Flurazepam in Dogs. Pharmacology, 1988, 36, 166-171.	0.9	4
642	Arithmetic Versus Harmonic Mean Values of Elimination Halfâ€Life: A Study of Triazolam. Journal of Clinical Pharmacology, 1989, 29, 655-656.	1.0	4
643	Validity of a Two-Point Acetaminophen Pharmacokinetic Study. Therapeutic Drug Monitoring, 1990, 12, 35-39.	1.0	4
644	The Safety of Over-the-Counter Drugs: Some Reflections and Unanswered Questions. Journal of Clinical Psychopharmacology, 2003, 23, 111-112.	0.7	4
645	Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate. Biopharmaceutics and Drug Disposition, 2010, 31, 72-81.	1.1	4
646	Explaining Some Journal Requirements. Clinical Pharmacology in Drug Development, 2012, 1, 119-120.	0.8	4
647	Grapefruit–medication interactions. Cmaj, 2013, 185, 507.1-507.	0.9	4
648	Regression and Correlation. Clinical Pharmacology in Drug Development, 2015, 4, 161-162.	0.8	4

#	Article	IF	CITATIONS
649	Opportunistic Journals in the Clinical Pharmacology Space. Journal of Clinical Pharmacology, 2018, 58, 567-571.	1.0	4
650	Resveratrol glucuronidation <i>in vitro</i> : potential implications of inhibition by probenecid. Journal of Pharmacy and Pharmacology, 2019, 71, 371-378.	1.2	4
651	Newer Antidepressants. Journal of Clinical Psychopharmacology, 1997, 17, 75-77.	0.7	4
652	Psychopharmacologic Management of Anxiety in the Cardiac Patient. Psychiatry in Medicine, 1971, 2, 55-66.	0.4	3
653	Ibuprofen Does Not Impair Antipyrine Clearance. Journal of Clinical Pharmacology, 1983, 23, 517-522.	1.0	3
654	Lithium and the Newborn Heart. Journal of Clinical Psychopharmacology, 1990, 10, 311.	0.7	3
655	Influence of vitamin E supplementation on antipyring clearance in the cebus monkey. Nutrition Research, 1990, 10, 1045-1051.	1.3	3
656	Role of CYP3A enzymes in the biotransformation of triazolam in rat liver. Xenobiotica, 2004, 34, 463-471.	0.5	3
657	Pharmacokinetic determinants of hypnotic drug action: The art and science of controlling release. Sleep Medicine, 2006, 7, S10-S14.	0.8	3
658	Pharmacokinetic profile of SKPâ€1041, a modified release formulation of zaleplon. Biopharmaceutics and Drug Disposition, 2011, 32, 489-497.	1.1	3
659	The Seventy-Kilogram Fantasy. Clinical Pharmacology in Drug Development, 2013, 2, 101-102.	0.8	3
660	Opioid Prescribing: What Are the Numbers?. Clinical Pharmacology in Drug Development, 2018, 7, 6-8.	0.8	3
661	Opportunistic Journals in the Clinical Pharmacology Space. Clinical Pharmacology in Drug Development, 2018, 7, 353-357.	0.8	3
662	Mechanism of dasabuvir inhibition of acetaminophen glucuronidation. Journal of Pharmacy and Pharmacology, 2022, 74, 131-138.	1.2	3
663	Epiphenomenal, Causal, or Correlational-More on the Mechanism(s) of Action of Antidepressants. Journal of Clinical Psychopharmacology, 1998, 18, 265-267.	0.7	3
664	Short- and Long-Acting Oral Quinidine Preparations. Angiology, 1978, 29, 243-250.	0.8	2
665	Propranolol??s Psychiatric Side Effects. Journal of Clinical Psychopharmacology, 1983, 3, 65.	0.7	2
666	Distribution. Journal of Clinical Pharmacology, 1986, 26, 425-426.	1.0	2

#	Article	IF	CITATIONS
667	New Pharmacokinetic Methods: L Estimation of Mean Serum Concentration From Trough Serum Concentration. Journal of Clinical Pharmacology, 1990, 30, 482-488.	1.0	2
668	Pharmacokinetic and dynamic correlates of intravenous alprazolam challenge. Clinical Pharmacology and Therapeutics, 1991, 50, 656-662.	2.3	2
669	Clinical Therapeutic Conference: Pharmacokinetic Principles in Clinical Medicine. Journal of Clinical Pharmacology, 1992, 32, 118-123.	1.0	2
670	Baseline Plasma GABA: Its Relationship to the Adverse Effects of Acute Lorazepam Administration on Cognition in the Elderly. Neurochemical Research, 2004, 29, 2311-2315.	1.6	2
671	Clinical Pharmacology in Drug Development. Clinical Pharmacology in Drug Development, 2012, 1, 3-3.	0.8	2
672	Clinical pharmacology in drug development — an update. Clinical Pharmacology in Drug Development, 2015, 4, 243-244.	0.8	2
673	A soft benzodiazepine. Clinical Pharmacology in Drug Development, 2015, 4, 81-82.	0.8	2
674	Aspartame — Is there new information?. Clinical Pharmacology in Drug Development, 2015, 4, 1-1.	0.8	2
675	Inhibitory effects of sulfonylureas and nonâ€steroidal antiâ€inflammatory drugs on <i>in vitro</i> metabolism of canagliflozin in human liver microsomes. Biopharmaceutics and Drug Disposition, 2018, 39, 135-142.	1.1	2
676	Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	2
677	The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator. Clinical Pharmacology in Drug Development, 2020, 9, 1015-1024.	0.8	2
678	Reduced Clearance of Quinidine in Elderly Humans. Verhandlungen Der Deutschen Gesellschaft Fur Kreislaufforschung, 1977, 43, 426-426.	0.1	2
679	Rational Use of Psychotropic Drugs III. Major Tranquilizers. American Journal of Health-System Pharmacy, 1974, 31, 1226-1232.	0.5	1
680	Rational Use of Psychotropic Drugs II. Antianxiety Agents. American Journal of Health-System Pharmacy, 1974, 31, 1077-1084.	0.5	1
681	The clinical use of procainamide. American Journal of Health-System Pharmacy, 1974, 31, 889-894.	0.5	1
682	Pharmacotherapy of Essential Hypertension. American Journal of Health-System Pharmacy, 1975, 32, 508-517.	0.5	1
683	Rational Use of psychotropic drugs IV. Antidepressants. American Journal of Health-System Pharmacy, 1975, 32, 59-64.	0.5	1

0.9 1

#	Article	IF	CITATIONS
685	Pharmacokinetics and bioavailability of ciramadol, a new analgesic. Drug Development Research, 1985, 6, 61-66.	1.4	1
686	Comment: Triazolam-Cimetidine Reaction. Drug Intelligence & Clinical Pharmacy, 1985, 19, 679-679.	0.4	1
687	In Vitro Approaches to Anticipating Clinical Drug Interactions. , 0, , 31-74.		1
688	Ethanol inhibits in-vitro metabolism of nifedipine, triazolam and testosterone in human liver microsomesâ€. Journal of Pharmacy and Pharmacology, 2010, 56, 963-966.	1.2	1
689	Regulatory and Scientific Aspects of Drugâ€Drug Interaction Studies. Clinical Pharmacology in Drug Development, 2012, 1, 43-44.	0.8	1
690	American College of Clinical Pharmacology commentary on theStrategic Plan 2010-2014 Progress Reportfrom the Office of Dietary Supplements, National Institutes of Health. Journal of Clinical Pharmacology, 2015, 55, 723-724.	1.0	1
691	Elements of a Good Scientific Paper. Journal of Clinical Psychopharmacology, 2016, 36, 539-541.	0.7	1
692	The Life of Milton Greenblatt. Journal of Clinical Psychopharmacology, 1995, 15, 155-159.	0.7	1
693	Mass Units or Molar Units for Drug Concentration?. Journal of Clinical Psychopharmacology, 1999, 19, 1-2.	0.7	1
694	The Specificity of the Extraction Fluorescence Assay for Serum or Plasma Quinidine. Journal of Clinical Pharmacology, 1981, 21, 333-336.	1.0	0
695	Gas chromatographic analysis of underivatized tocainide. Biomedical Applications, 1987, 419, 339-344.	1.7	0
696	Pharmacodynamic Comparison of <scp>l</scp> â€Bunolol with Propranolol, Metoprolol, and Placebo. Journal of Clinical Pharmacology, 1988, 28, 1101-1105.	1.0	0
697	A Possible New Approach to the Treatment of. Journal of Clinical Psychopharmacology, 1992, 12, 155.	0.7	0
698	Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin. Journal of Pharmacy and Pharmacology, 2010, 55, 1707-1707.	1.2	0
699	A Tribute to Dr. Hermann R. Ochs, 1943–2013. Journal of Clinical Psychopharmacology, 2014, 34, 669-670.	0.7	0
700	Editors' Note Regarding Publication Delay. Journal of Clinical Psychopharmacology, 2014, 34, 671.	0.7	0
701	<i>Clinical Pharmacology in Drug Development</i> : Five Years in the Books. Clinical Pharmacology in Drug Development, 2016, 5, 432-434.	0.8	0
702	The <i>Journal of Clinical Pharmacology, Clinical Pharmacology in Drug Development</i> , and the Impact Factor. Clinical Pharmacology in Drug Development, 2017, 6, 218-219.	0.8	0

#	Article	IF	CITATIONS
703	Recent Recall of a Generic Form of Extended-Release Paliperidone. Journal of Clinical Psychopharmacology, 2017, 37, 493-494.	0.7	0
704	Is There Always a Right or Wrong?. Journal of Clinical Psychopharmacology, 2018, 38, 545-546.	0.7	0
705	Public Health Risk of Designer Psychotropic Drugs: Should PHASE Be Phased In?. Clinical Pharmacology and Therapeutics, 2019, 106, 1175-1176.	2.3	Ο
706	A Randomized, Double-Blind Trial of the Interaction between Cranberry Juice and Warfarin Blood, 2006, 108, 4125-4125.	0.6	0
707	Identification of Human Cd8+ and Cd4+ Lymphocytes with Unique Drug Resistance Activity by Imaging the Drug Transport Kinetics at the Single Cell Resolution Blood, 2006, 108, 3894-3894.	0.6	Ο
708	Evidence for epigenetic regulation of UGT1A1 protein expression and activity in healthy human livers. FASEB Journal, 2013, 27, 270.5.	0.2	0
709	HPLC Determination of Beta-Adrenergic Blockers in Biological Fluids. Techniques and Instrumentation in Analytical Chemistry, 1989, 4, 159-187.	0.0	0
710	Comment on the Next Chapter of the Journal of Clinical Psychopharmacology. Journal of Clinical Psychopharmacology, 2020, 40, 528-528.	0.7	0